Publicaciones

Yang J, Xu K, Seiffert D.
Challenges and promises of developing thrombin receptor antagonists.
Recent Pat Cardiovasc Drug Discov.2010 Nov 1;5(3):162-70.

Abdel-Razeq HN, Hijjawi SB, Jallad SG, Ababneh BA.
Venous thromboembolism risk stratification in medically-ill hospitalized cancer patients. A comprehensive cancer center experience.
J Thromb Thrombolysis. 2010 Oct;30(3):286-93

Andersen KK, Andersen ZJ, Olsen TS.
Age- and Gender-Specific Prevalence of Cardiovascular Risk Factors in 40 102 Patients With First-Ever Ischemic Stroke. A Nationwide Danish Study.
Stroke. 2010 Oct 21. [Epub ahead of print]

Barrett YC, Wang Z, Frost C, Shenker A.
Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay.
Thromb Haemost. 2010 Oct 26;104(6). [Epub ahead of print]

Becker RC, Gibson CM, Jennings LK, Morrow DA.
Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions.
Am J Cardiol. 2010 Oct 15;106(8):S2-3.

Broukhim M, Halperin JL.
Stroke Prevention in the High-risk Atrial Fibrillation Patient: Medical Management.
Curr Cardiol Rep. 2010 Oct 15. [Epub ahead of print]

Cohen AT.
Asia-Pacific Thrombosis Advisory Board consensus paper on prevention of venous thromboembolism after major orthopaedic surgery.
Thromb Haemost. 2010 Oct 12;104(5). [Epub ahead of print]

De Breucker S, Herzog G, Pepersack T.
Could geriatric characteristics explain the under-prescription of anticoagulation therapy for older patients admitted with atrial fibrillation? A retrospective observational study.
Drugs Aging. 2010 Oct 1;27(10):807-13. doi: 10.2165/11537900-000000000-00000.

Dobesh P.
The importance of appropriate prophylaxis for the prevention of venous thromboembolism in at-risk medical patients.
Int J Clin Pract. 2010 Oct;64(11):1554-62. doi: 10.1111/j.1742-1241.2010.02447.x.

Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Iorio A.
Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.
Ann Intern Med. 2010 Oct 19;153(8):523-31.

Eagle KA, Cannom DS, Garcia DA.
Management of Atrial Fibrillation: Translating Clinical Trial Data into Clinical Practice
Am J Med. 2010 Oct 5. [Epub ahead of print]

Eriksson M, Stecksén A, Glader EL, Norrving B, Appelros P, Hulter Åsberg K, Stegmayr B, Terént A, Asplund K; for the Riks-Stroke Collaboration.
Discarding Heparins as Treatment for Progressive Stroke in Sweden 2001 to 2008.
Stroke. 2010 Nov;41(11):2552-2558. Epub 2010 Oct 7

Ezekowitz MD, Aikens TH, Brown A, Ellis Z.
The evolving field of stroke prevention in patients with atrial fibrillation.
Stroke. 2010 Oct;41(10 Suppl):S17-20.

Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE.
Warfarin Discontinuation After Starting Warfarin for Atrial Fibrillation.
Circ Cardiovasc Qual Outcomes. 2010 Oct 19. [Epub ahead of print]

Green L, Lawrie AS, Patel S, Hossain F, Chitolie A, Mackie IJ, Haddad FS, Machin SJ.
The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation.
Br J Haematol. 2010 Oct 18. [Epub ahead of print]

Hillarp A, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL.
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
J Thromb Haemost. 2010 Oct 7. [Epub ahead of print]

Huang J, Cao Y, Liao C, Wu L, Gao F.
Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.
Thromb Haemost. 2010 Oct 12;105(1). [Epub ahead of print]

Huisman MV, Quinlan DJ, Dahl OE, Schulman S.
Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty: Results of Separate Pooled Analyses of Phase III Multicenter Randomized Trials.
Circ Cardiovasc Qual Outcomes. 2010 Oct 5. [Epub ahead of print]

Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, Siragusa S, Palareti G.
Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review.
Arch Intern Med. 2010 Oct 25;170(19):1710-6.

Kleijer BC, Heerdink ER, Egberts TC, Jansen PA, van Marum RJ.
Antipsychotic drug use and the risk of venous thromboembolism in elderly patients.
J Clin Psychopharmacol. 2010 Oct;30(5):526-30.

Lip GY, Frison L, Halperin JL, Lane DA.
Identifying Patients at High Risk for Stroke Despite Anticoagulation. A Comparison of Contemporary Stroke Risk Stratification Schemes in an Anticoagulated Atrial Fibrillation Cohort.
Stroke. 2010 Oct 21. [Epub ahead of print]

Lowe GD.
Management of deep vein thrombosis to reduce the incidence of post-thrombotic syndrome.
Phlebology. 2010 Oct;25 Suppl 1:9-13.

Maestre A, Sánchez R, Rosa V, Aujesky D, Lorenzo A, Barillari G, Monreal M; RIETE Investigators.
Clinical characteristics and outcome of inpatients versus outpatients with venous thromboembolism: findings from the RIETE Registry.
Eur J Intern Med. 2010;21(5):377-82.

Marinigh R, Lip GY, Lane DA.
Stroke prevention in atrial fibrillation patients.
Expert Opin Pharmacother. 2010 Oct;11(14):2331-50

Nick AM, Schmeler KM, Frumovitz MM, Soliman PT, Spannuth WA, Burzawa JK, Coleman RL, Wei C, dos Reis R, Ramirez PT.
Risk of thromboembolic disease in patients undergoing laparoscopic gynecologic surgery.
Obstet Gynecol. 2010 D117 Oct;116(4):956-61. PubMed PMID: 20859161.

O'Connell C, Razavi P, Ghalichi M, Boyle S, Vasan S, Mark L, Caton A, Duddalwar V, Boswell W, Grabow K, Liebman HA.
Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging MDCT scanning.
J Thromb Haemost. 2010 Oct 18. doi: 10.1111/j.1538-7836.2010.04114.x. [Epub ahead of print] PubMed PMID: 20955348.

Piazza G, Goldhaber SZ.
Fibrinolysis for acute pulmonary embolism.
Vasc Med. 2010 Oct;15(5):419-28. PubMed PMID: 20926501.

Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM.
Treatments for stroke prevention in atrial fibrillation: A network meta-analyses and indirect comparisons versus dabigatran etexilate.
Thromb Haemost. 2010 Oct 21;102(2). [Epub ahead of print]

Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E.
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Am Heart J. 2010 Oct;160(4):635-41.

Samama MM, Kunitada S, Oursin A, Depasse F, Heptinstall S.
Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
Thromb Res. 2010 Oct;126(4):e286-93

Schellong SM, Haas S, Greinacher A, Schwanebeck U, Sieder C, Abletshauser C, Bramlage P, Riess H.
An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN.
Expert Opin Pharmacother. 2010 Oct 18. [Epub ahead of print]

Stein PD, Hull RD, Matta F, Willyerd GL.
Modest Response in Translation to Home Management of Deep Venous Thrombosis.
Am J Med. 2010 Oct 18. [Epub ahead of print] PubMed PMID: 20961524.

The Equinox Investigators.
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.
J Thromb Haemost. 2010 Oct 7. doi: 10.1111/j.1538-7836.2010.04100.x. [Epub ahead of print]

Tripodi A, Chantarangkul V, Guinet C, Samama MM.
The INR calibrated for Rivaroxaban-(INRrivaroxaban) has the potential to normalize PT results for Rivaroxaban-treated patients: results of an in-vitro study.
J Thromb Haemost. 2010 Oct 13. [Epub ahead of print]

Weber R, Diener HC, Weimar C.
Prevention of cardioembolic stroke in patients with atrial fibrillation.
Expert Rev Cardiovasc Ther. 2010 Oct;8(10):1405-15

Di Nisio M, Ferrante N, De Tursi M, Iacobelli S, Cuccurullo F, Büller HR, Feragalli B, Porreca E.
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Thromb Haemost. 2010;104(5).

Dobesh P.
The importance of appropriate prophylaxis for the prevention of venous thromboembolism in at-risk medical patients.
Int J Clin Pract. 2010;64(11):1554-1562.

Galanaud JP, Genty C, Sevestre MA, Brisot D, Lausecker M, Gillet JL, Rolland C, Righini M, Leftheriotis G, Bosson JL, Quere I; the OPTIMEV SFMV investigators.
Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis. The OPTIMEV study.
Thromb Haemost. 2010 Sep 30;105(1). [Epub ahead of print] PubMed PMID: 20886192.

Garcia DA, Lopes RD, Hylek EM.
New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs.
Thromb Haemost. 2010 Sep 30;104(6). [Epub ahead of print]

Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrøm SZ, Poulsen HE, Køber L, Torp-Pedersen C.
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Arch Intern Med. 2010;170(16):1433-41.

Janssen KJ, van der Velde EF, Ten Cate-Hoek AJ, Prins MH, van Weert HC, Stoffers HE, Büller HR, Oudega R, Hoes AW, Toll DB, Moons KG.
Optimisation of the diagnostic strategy for suspected deep-vein thrombosis in primary care.
Thromb Haemost. 2010 Sep 30;105(1). [Epub ahead of print] PubMed PMID: 20886183.

Lecumberri R, Soler S, Del Toro J, Barba R, Rosa V, Ciammaichella MM, Monreal M; the RIETE Investigators.
Effect of the time of diagnosis on outcome in patients with acute venous thromboembolism. Findings from the RIETE Registry.
Thromb Haemost. 2010 Sep 30;105(1). [Epub ahead of print]

Lip GY.
Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for Thromboprophylaxis in Atrial Fibrillation.
Am J Med. 2010 Sep 29. [Epub ahead of print]

Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA.
Age as a risk factor for stroke in atrial fibrillation patients implications for thromboprophylaxis: Implications for thromboprophylaxis.
J Am Coll Cardiol. 2010;56(11):827-37.

Sadanaga T, Kohsaka S, Ogawa S.
D-dimer levels in combination with clinical risk factors can effectively predict subsequent thromboembolic events in patients with atrial fibrillation during oral anticoagulant therapy.
Cardiology. 2010;117(1):31-6. Epub 2010 Sep 30

Samama MM.
The mechanism of action of rivaroxaban - an oral, direct Factor Xa inhibitor - compared with other anticoagulants.
Thromb Res. 2010 Sep 29. [Epub ahead of print]

Tick LW, Doggen CJ, Rosendaal FR, Faber WR, Bousema MT, Mackaay AJ, Van Balen P, Kramer MH.
Predictors of the post-thrombotic syndrome with non-invasive venous examinations in patients six weeks after a first episode of deep venous thrombosis.
J Thromb Haemost. 2010 Sep 22. [Epub ahead of print]

Weitz JI, Cao C, Eriksson BI, Fisher W, Kupfer S, Raskob G, Spaeder J, Turpie AG.
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
Thromb Haemost. 2010 Sep 30;104(6). [Epub ahead of print]

Wittkowsky AK, Spinler SA, Dager W, Gulseth MP, Nutescu EA.
Dosing guidelines, not protocols, for managing warfarin therapy.
Am J Health Syst Pharm. 2010;67(18):1554-6.

van Es J, Douma RA, Gerdes VE, Kamphuisen PW, Büller HR; Medscape.
Acute pulmonary embolism. Part 2: treatment.
Nat Rev Cardiol. 2010 Sep 14. [Epub ahead of print]

Agarwal V, Phung OJ, Tongbram V, Bhardwaj A, Coleman CI
Statin use and the prevention of venous thromboembolism: a meta-analysis.
Int J Clin Pract. 2010;64(10):1375-83.

Bacci C, Maglione M, Favero L, Perini A, Di Lenarda R, Berengo M, Zanon E.
Management of patients undergoing anticoagulant treatment. Results from a large, multicentre, prospective, case-control study.
Thromb Haemost. 2010 Aug 30;104(5). [Epub ahead of print]

Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, De Bon E, Tormene D, Pagnan A, Prandoni P.
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: The Padua Prediction Score.
J Thromb Haemost. 2010 Aug 25. [Epub ahead of print]

Baser O, Supina D, Sengupta N, Wang L, Kwong L
Impact of postoperative venous thromboembolism on Medicare recipients undergoing total hip replacement or total knee replacement surgery.
Am J Health Syst Pharm. 2010;67(17):1438-45.

Becker RC, Alexander JH, Newby K, Yang H, Barrett Y, Mohan P, Wang J, Harrington RA, Wallentin LC.
Effect of apixaban, an oral and direct Factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
Thromb Haemost. 2010 Aug 30;104(5). [Epub ahead of print]

Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H.
Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Thromb Haemost. 2010 Aug 30;104(4). [Epub ahead of print]

Erkens PM, Gandara E, Wells P, Shen AY, Bose G, Le Gal G, Rodger M, Prins MH, Carrier M.
Safety of outpatient treatment in acute pulmonary embolism.
J Thromb Haemost. 2010 Aug 23. [Epub ahead of print]

Fuji T, Fujita S, Tachibana S, Kawai Y
A dose-ranging study evaluating the oral Factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.
J Thromb Haemost. 2010 Aug 12. [Epub ahead of print]

Huo MH, Spyropoulos AC
The eighth American College of Chest Physicians guidelines on venous thromboembolism prevention: implications for hospital prophylaxis strategies.
J Thromb Thrombolysis. 2010 Aug 5. [Epub ahead of print]

Kuzniatsova N, Lip GY.
How do we get better at identifying patients with atrial fibrillation who are at 'truly low risk' or 'truly high risk' of stroke?
J Neurol Sci. 2010 Aug 30. [Epub ahead of print]

Levy JH, Key NS, Azran MS
Novel oral anticoagulants: Implications in the perioperative setting.
Anesthesiology. 2010 Aug 9. [Epub ahead of print]

Linkins L, O'Donnell M, Julian JA, Kearon C
Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy.
J Thromb Haemost. 2010 Aug 12. [Epub ahead of print]

Löwenberg EC, Meijers JC, Monia BP, Levi M.
Coagulation Factor XI as a novel target for antithrombotic treatment.
J Thromb Haemost. 2010 Aug 17. [Epub ahead of print]

Marinigh R, Lip GY, Lane DA
Stroke prevention in atrial fibrillation patients.
Expert Opin Pharmacother. 2010 Aug 18. [Epub ahead of print]

Marsh JD, Keyrouz SG
Stroke prevention and treatment.
J Am Coll Cardiol. 2010;56(9):683-691.

Naccarato M, Chiodo Grandi F, Dennis M, Sandercock PA
Physical methods for preventing deep vein thrombosis in stroke.
Cochrane Database Syst Rev. 2010;8:CD001922.

Panova-Noeva M, Falanga A
Treatment of thromboembolism in cancer patients.
Expert Opin Pharmacother. 2010;11(12):2049-58

Romualdi E, Ageno W
Oral Xa Inhibitors.
Hematol Oncol Clin North Am. 2010;24(4):727-737

Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F.
An optimised, rapid chromogenic assay, specific for measuring direct Factor Xa inhibitors (rivaroxaban) in plasma.
Thromb Haemost. 2010 Aug 30;104(5). [Epub ahead of print]

Siracuse JJ, Robich MP, Gautum S, Kasper EM, Moorman DW, Hauser CJ
Antiplatelet agents, warfarin, and epidemic intracranial hemorrhage.
Surgery. 2010 Aug 19. [Epub ahead of print]

Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; on behalf of the RE-LY investigators.
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
Lancet. 2010 Aug 27. [Epub ahead of print]

Weber R, Diener HC.
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
J Cell Mol Med. 2010 Aug 25. [Epub ahead of print]

Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral Factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
Thromb Haemost. 2010;104(3). [Epub ahead of print]

Zhang H, Löwenberg EC, Crosby JR, Macleod AR, Zhao C, Gao D, Black C, Revenko AS, Meijers JC, Stroes ES, Levi M, Monia BP.
Inhibition of the intrinsic coagulation pathway Factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.
Blood. 2010 Aug 31. [Epub ahead of print]

Ahrens I, Lip GY, Peter K
New oral anticoagulant drugs in cardiovascular disease.
Thromb Haemost 2010;104(1)

Ait Mokhtar O, Bonello L, Armero S, Sbragia P, Paganelli F
Early and late outcomes of clopidogrel and coumadin combination for patients on oral anticoagulants undergoing coronary stenting.
Cardiovasc Revasc Med. 2010;11(3):159-62

Bauer KA
New oral anticoagulants in development: potential for improved safety profiles.
Rev Neurol Dis 2010;7(1):1-8

Bereznicki LR, Peterson GM
New antithrombotics for atrial fibrillation.
Cardiovasc Ther. 2010 Jul 14. [Epub ahead of print]

Dean SM, Abraham W
Venous thromboembolic disease in congestive heart failure.
Congest Heart Fail. 2010;16(4):164-9.

Dubois EA, Cohen AF
Dabigatran etexilate.
Br J Clin Pharmacol. 2010;70(1):14-5

Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J
Dabigatran: An oral novel potent reversible nonpeptide inhibitor of thrombin.
Arterioscler Thromb Vasc Biol. 2010 Jul 29. [Epub ahead of print]

Garcia-Ortega P, Asencio J
Dabigatran offers the simplest solution for thromboprophylaxis after orthopaedic surgery in patients allergic to low-molecular-weight heparins.
Br J Haematol. 2010 Jul 7 [Epub ahead of print]

Kapoor A, Chuang W, Radhakrishnan N, Smith KJ, Berlowitz D, Segal JB, Katz JN, Losina E
Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
Pharmacoeconomics. 2010;28(7):521-38

Konishi N, Hiroe K, Kawamura M
Differential effects of TAK-442, a novel orally active direct Factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on Factor V-mediated feedback on coagulation cascade and bleeding.
Thromb Haemost. 2010 Jul 20;104(3)[Epub ahead of print]

Lee CJ, Badhwar G, Ansell JE
Oral IIa inhibitors.
Hematol Oncol Clin North Am. 2010;24(4):739-53, ix.

Lip GY, Lane DA
Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
Am J Med. 2010 Jul 21 [Epub ahead of print]

Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY
Underuse of oral anticoagulants in atrial fibrillation: a systematic review.
Am J Med. 2010;123(7):638-645

Poli D, Lip GY, Antonucci E, Grifoni E, Lane D
Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population.
J Cardiovasc Electrophysiol. 2010 Jul 23. [Epub ahead of print]

Röther J, Crijns H
Prevention of stroke in patients with atrial fibrillation: the role of new antiarrhythmic and antithrombotic drugs.
Cerebrovasc Dis. 2010;30(3):314-22

Schulman S, Anderson DR, Bungard TJ, Jaeger T, Kahn SR, Wells P, Jo-Anne Wilson S
Direct and indirect costs of management of long-term warfarin therapy in Canada.
J Thromb Haemost. 2010 Jul 16. [Epub ahead of print]

Walfridsson H, Johansson B, Englund A, Kennebäck G, Schwieler J, Kongstad O, Wåhlander K, Malm AR, Edvardsson N
Effects of AZD0837, a novel direct thrombin inhibitor, on the electrophysiological properties of the human heart: A randomized, double-blind, parallel-group, placebo-controlled study.
Clin Drug Investig. 2010;30(7):461-71

Walsh TS, Stanworth SJ, Prescott RJ, Lee RJ, Watson DM, Wyncoll D, Writing Committee of the Intensive Care Study of Coagulopathy (ISOC) Investigators
Prevalence, management, and outcomes of critically ill patients with prothrombin time prolongation in United Kingdom intensive care units.
Crit Care Med. 2010 Jul 15 [Epub ahead of print]

Arnold JD, Dart BW, Barker DE, Maxwell RA, Burkholder HC, Mejia VA, Smith PW, Longley JM
Gold Medal Forum Winner. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients.
Am Surg. 2010;76(6)

Asberg S, Henriksson KM, Farahmand B, Asplund K, Norrving B, Appelros P, Stegmayr B, Hulter Åsberg K, Terént A
Ischemic stroke and secondary prevention in clinical practice. A cohort study of 14,529 patients in the Swedish Stroke Register
Stroke 2010 Jun 3 [Epub ahead of print]

Benavente L, Calleja S, de la Vega V, Garcia-Garcia J, Lahoz CH
Oral anticoagulation in elderly patients as secondary prevention of cardioembolic strokes.
Int Arch Med 2010;3(1):8

Dahl OE, Huisman MV
Dabigatran etexilate: advances in anticoagulation therapy.
Expert Rev Cardiovasc Ther. 2010;8(6):771-4

Dahl OE, Quinlan DJ, Bergqvist D, Eikelboom JW
A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty.
J Thromb Haemost. 2010 Jun 24 [Epub ahead of print]

Ebner T, Wagner K, Wienen W
Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability and pharmacological activity.
Drug Metab Dispos. 2010 Jun 15 [Epub ahead of print]

Fanikos J, Stevens LA, Labreche M, Piazza G, Catapane E, Novack L, Goldhaber SZ
Adherence to pharmacological thromboprophylaxis orders in hospitalized patients.
Am J Med. 2010;123(6):536-41.

George J, Doney A, Palmer CN, Lang CC
Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin.
Cardiovasc Ther. 2010;28(3):135-8

Karthikeyan G, Eikelboom JW
Apixaban in acute coronary syndromes.
Cardiovasc Ther. 2010 Jun 11 [Epub ahead of print]

Kovacs MJ, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, Solymoss S, Crowther M, Perrier A, Ramsay T, Betancourt MT, Rodger MA
Patients with a first symptomatic unprovoked DVT are at higher risk of recurrent VTE than patients with a first unprovoked PE.
J Thromb Haemost. 2010 Jun 19. [Epub ahead of print]

Levy JH, Azran M
Anesthetic concerns for patients with coagulopathy.
Curr Opin Anaesthesiol. 2010;23(3):400-5

Michelena HI, Powell BD, Brady PA, Friedman PA, Ezekowitz MD
Gender in atrial fibrillation: Ten years later.
Gend Med. 2010;7(3):206-217

Novacek G, Weltermann A, Sobala A, Tilg H, Petritsch W, Reinisch W, Mayer A, Haas T, Kaser A, Feichtenschlager T, Fuchssteiner H, Knoflach P, Vogelsang H, Miehsler W, Platzer R, Tillinger W, Jaritz B, Schmid A, Blaha B, Dejaco C, Eichinger S
Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism.
Gastroenterology. 2010 Jun 11 [Epub ahead of print]

Paikin JS, Eikelboom JW, Cairns JA, Hirsh J
New antithrombotic agents-insights from clinical trials.
Nat Rev Cardiol. 2010 Jun 29. [Epub ahead of print]

Piccini JP, Lopes RD, Mahaffey KW
Oral Factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Curr Opin Cardiol 2010 Jun 1. [Epub ahead of print]

Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI
Oral direct Factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Thromb Haemost. 2010 Jun 29

Robinson MT, Rabinstein AA, Meschia JF, Freeman WD
Safety of recombinant activated Factor VII in patients with warfarin-associated hemorrhages of the central nervous system.
Stroke. 2010 Jun 3 [Epub ahead of print]

Rose P, McManus A, Arya R, Scriven N, Farren T, Nokes T, Bacon S, Cooper D, O'Shaughnessy D, Paneesha S
Risk factors for cancer-associated venous thromboembolism in outpatient deep venous thrombosis clinics.
Br J Haematol. 2010 Jun 17. [Epub ahead of print]

Sattari M, Lowenthal DT
Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.
Am J Ther. 2010 Jun 9 [Epub ahead of print]

Schützer KM, Svensson MK, Zetterstrand S, Eriksson UG, Wåhlander K
Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837.
Eur J Clin Pharmacol. 2010 Jun 10 [Epub ahead of print]

Shah MA, Capanu M, Soff G, Asmis T, Kelsen D
Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies.
J Thromb Haemost. 2010 Jun 14 [Epub ahead of print]

Siddiqui FM, Qureshi AI.
Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
Expert Opin Pharmacother. 2010 Jun;11(8):1403-11.

Thomas S, Van Kampen M
Should orthopedic outpatients with lower limb casts be given deep vein thrombosis prophylaxis?
Clin Appl Thromb Hemost. 2010 Jun 13 [Epub ahead of print]

Treasure T, Hill J
NICE guidance on reducing the risk of venous thromboembolism in patients admitted to hospital.
J R Soc Med. 2010;103(6):210-2

Walenga JM, Adiguzel C
Drug and dietary interactions of the new and emerging oral anticoagulants.
Int J Clin Pract. 2010;64(7):956-67

Wong PC, Jiang X
Apixaban, a direct Factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: Comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Thromb Haemost. 2010 Jun 29;104. [Epub ahead of print]

Wong PC, Luettgen JM, Rendina AR, Kettner CA, Xin B, Knabb RM, Wexler R, Priestley ES
BMS-593214, an active site-directed Factor VIIa inhibitor: Enzyme kinetics, antithrombotic and antihaemostatic studies.
Thromb Haemost. 2010 Jun 29;104. [Epub ahead of print]

Aliot E, Breithardt G, Brugada J, Camm J, Lip GY, Vardas PE, Wagner M; Atrial Fibrillation AWareness And Risk Education group; Atrial Fibrillation Association; European Heart Rhythm Association; Stroke Alliance for Europe; World Heart Federation.
An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality.
Europace. 2010 May;12(5):626-33.

Becattini C, Lignani A, Agnelli G
New anticoagulants for the prevention of venous thromboembolism.
Drug Des Devel Ther 2010;4:49-60

Borris LC
Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
Arch Orthop Trauma Surg 2010;130(5):583-9

Carrier M, Le Gal G, Wells PS, Rodger MA.
Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism.
Ann Intern Med. 2010 May 4;152(9):578-89.

Chong CT, Lew TW, Kuperan P, Tan JJ, Tan HL, Kwek TK
Rapid reversal of coagulopathy in warfarin-related intracranial haemorrhages with prothrombin complex concentrates.
Anaesth Intensive Care 2010;38(3):474-80

Crowther MA, Garcia D, Ageno W, Wang L, Witt DM, Clark NP, Blostein MD, Kahn SR, Schulman S, Kovacs M, Rodger MA, Wells P, Anderson D, Ginsberg J, Selby R, Siragusa S, Silingardi M, Dowd MB, Kearon C.
Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study.
Thromb Haemost. 2010 May 10;104(1). [Epub ahead of print]

Cushman M, Callas PW, Denenberg JO, Bovill EG, Criqui MH.
Risk factors for peripheral venous disease resemble those for venous thrombosis: the San Diego population study.
J Thromb Haemost. 2010 May 21. [Epub ahead of print]

Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, Merli GJ, Monreal M, Nakamura M, Pavanello R, Pini M, Piovella F, Spencer FA, Spyropoulos AC, Turpie AG, Zotz RB, Fitzgerald G, Anderson FA; for the IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) Investigators.
Factors at Admission Associated With Bleeding Risk in Medical Patients: Findings From IMPROVE.
Chest. 2010 May 7. [Epub ahead of print]

Desai HV, Aronow WS, Gandhi K, Bakerywala S, Laimuanpuii J, Sharma M, Peterson SJ.
Association of warfarin use with CHADS(2) score in 441 patients with nonvalvular atrial fibrillation and no contraindications to warfarin.
Prev Cardiol. 2010 Fall;13(4):172-4. doi: 10.1111/j.1751-7141.2010.00073.x.

Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, Clemens A, Hantel S, Schnee JM, Eriksson BI; for the RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees.
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials.
Thromb Res 2010 May 14. [Epub ahead of print]

Harber CR, Nathanson MH
Rivaroxaban for thromboembolism prophylaxis after orthopaedic surgery.
Anaesthesia. 2010;65(6):552-5

Healy B, Beasley R, Weatherall M
Venous thromboembolism following prolonged cast immobilisation for injury to the tendo Achillis.
J Bone Joint Surg Br. 2010 May;92(5):646-50

Kamel H, Hegde M, Johnson DR, Gage BF, Johnston SC
Cost-effectiveness of outpatient cardiac monitoring to detect atrial fibrillation after ischemic stroke.
Stroke. 2010 May 27 [Epub ahead of print]

Karthikeyan G, Eikelboom JW.
The CHADS2 score for stroke risk stratification in atrial fibrillation - friend or foe?
Thromb Haemost. 2010 May 10;104(1). [Epub ahead of print]

Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marín F.
Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
Eur Heart J. 2010 May 6. [Epub ahead of print]

McNally MA
The impact of national guidelines for the prophylaxis of venous thromboembolism on the complications of arthroplasty of the lower limb.
J Bone Joint Surg Br. 2010;92(5):747

Orfeo T, Butenas S, Brummel-Ziedins KE, Gissel M, Mann KG
Anticoagulation by Factor Xa inhibitors.
J Thromb Haemost. 2010 May 21 [Epub ahead of print]

Payne JH
Aspects of anticoagulation in children.
Br J Haematol. 2010 May 26 [Epub ahead of print]

Ruff CT, Braunwald E.
Will Warfarin Ever Be Replaced?
J Cardiovasc Pharmacol Ther. 2010 May 18. [Epub ahead of print]

Sadanaga T, Sadanaga M, Ogawa S.
Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy.
J Am Coll Cardiol. 2010 May 18;55(20):2225-31.

Smith DE, Borg Xuereb C, Pattison HM, Lip GY, Lane DA.
Trial of an educational intervention on patients' knowledge of atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT).
BMC Cardiovasc Disord. 2010 May 20;10(1):21. [Epub ahead of print]

Stein PD, Matta F, Musani MH, Diaczok B.
Silent pulmonary embolism in patients with deep venous thrombosis: a systematic review.
Am J Med. 2010 May;123(5):426-31.

Traby L, Kaider A, Schmid R, Kranz A, Quehenberger P, Kyrle PA, Eichinger S.
The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial.
Thromb Haemost. 2010 May 10;104(1). [Epub ahead of print]

Trujillo TC
Emerging anticoagulants for venous thromboembolism prevention.
Am J Health Syst Pharm 2010;67(10 Suppl 6):S17-25

Uchiyama S, Shibata Y, Hirabayashi T, Mihara B, Hamashige N, Kitagawa K, Goto S, Origasa H, Shimada K, Kobayashi H, Isozaki M, Ikeda Y; J-TRACE Investigators.
Risk factor profiles of stroke, myocardial infarction, and atrial fibrillation: a Japanese Multicenter Cooperative Registry.
J Stroke Cerebrovasc Dis. 2010 May;19(3):190-7.

Zimetbaum PJ, Thosani A, Yu HT, Xiong Y, Lin J, Kothawala P, Emons M.
Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?
Am J Med. 2010 May;123(5):446-53.

Amin A, Spyropoulos AC, Dobesh P, Shorr A, Hussein M, Mozaffari E, Benner JS.
Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start).
J Thromb Thrombolysis 2010 Apr;29(3):326-39.

Baglin T.
Defining the population in need of thromboprophylaxis - making hospitals safer.
Br J Haematol. 2010 Apr 26. [Epub ahead of print]

Bauersachs RM, Riess H, Hach-Wunderle V, Gerlach H, Carnarius H, Eberle S, Rabe E, Schellong SM
Impact of gender on the clinical presentation and diagnosis of deep-vein thrombosis.
Thromb Haemost. 2010;103(4):710-7

Bergmann JF, Cohen AT, Tapson VF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang B, Anderson FA Jr, ENDORSE Investigators
Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey.
Thromb Haemost. 2010;103(4):736-48

Billett HH, Scorziello BA, Giannattasio ER, Cohen HW.
Low molecular weight heparin bridging for atrial fibrillation: is VTE thromboprophylaxis the major benefit?
J Thromb Thrombolysis. 2010 Apr 20. [Epub ahead of print]

Browne AM, Cronin CG, English C, Nimhuircheartaigh J, Murphy JM, Bruzzi JF.
Unsuspected Pulmonary Emboli in Oncology Patients Undergoing Routine Computed Tomography Imaging
J Thorac Oncol. 2010 Apr 23. [Epub ahead of print]

Brækkan SK, Borch KH, Mathiesen EB, Njølstad I, Wilsgaard T, Hansen JB.
Body Height and Risk of Venous Thromboembolism: The Tromso Study.
Am J Epidemiol. 2010 Apr 23. [Epub ahead of print]

Cohen H, Machin SJ
Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?
Lupus 2010;19(4):486-91

Coleman R, MacCallum P.
Treatment and secondary prevention of venous thromboembolism in cancer.
Br J Cancer 2010 Apr 13;102 Suppl 1:S17-23.

Eichinger S, Heinze G, Jandeck LM, Kyrle PA.
Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model.
Circulation 2010 Apr 13;121(14):1630-6. Epub 2010 Mar 29.

Epstein RS, Moyer TP, Aubert RE, O'Kane DJ, Xia F, Verbrugge RR, Gage BF, Teagarden JR.
Warfarin Genotyping Reduces Hospitalization Rates Results From the MM-WES (Medco-Mayo Warfarin Effectiveness Study).
J Am Coll Cardiol 2010 Apr 7. [Epub ahead of print]

Fauchier L, Lip GY.
Guidelines for antithrombotic therapy in atrial fibrillation: understanding the reasons for non-adherence and moving forwards with simplifying risk stratification for stroke and bleeding.
Europace 2010 Apr 12. [Epub ahead of print]

Friberg L, Hammar N, Rosenqvist M.
Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation.
Eur Heart J 2010 Apr;31(8):967-75. Epub 2009 Jan 27.

Kakkar AK, Macbeth F.
Antithrombotic therapy and survival in patients with malignant disease.
Br J Cancer. 2010 Apr 13;102 Suppl 1:S24-9.

Kowey PR, Reiffel JA, Myerburg R, Naccarelli GV, Packer DL, Pratt CM, Reiter MJ, Waldo AL; AFFECTS Scientific Advisory Committee and Investigators.
Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry).
Am J Cardiol 2010 Apr 15;105(8):1130-4. Epub 2010 Feb 20.

Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, Caldwell MD, Limdi N, Burmester JK, Dowd MB, Angchaisuksiri P, Bass AR, Chen J, Eriksson N, Rane A, Lindh JD, Carlquist JF, Horne BD, Grice G, Milligan PE, Eby C, Shin J, Kim H, Kurnik D, Stein CM, McMillin G, Pendleton RC, Berg RL, Deloukas P, Gage BF.
Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing.
Clin Pharmacol Ther 2010 Apr 7. [Epub ahead of print]

Lijfering WM, Middeldorp S, Veeger NJ, Hamulyák K, Prins MH, Büller HR, van der Meer J
Risk of Recurrent Venous Thrombosis in Homozygous Carriers and Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210A.
Circulation 2010 Apr 5. [Epub ahead of print]

Linkins LA, Weitz JI.
New and emerging anticoagulant therapies for venous thromboembolism.
Curr Treat Options Cardiovasc Med. 2010;12(2):142-55.

Lovelock CE, Cordonnier C, Naka H, Al-Shahi Salman R, Sudlow CL; The Edinburgh Stroke Study Group, Sorimachi T, Werring DJ, Gregoire SM, Imaizumi T, Lee SH, Briley D, Rothwell PM.
Antithrombotic Drug Use, Cerebral Microbleeds, and Intracerebral Hemorrhage. A Systematic Review of Published and Unpublished Studies.
Stroke. 2010 Apr 29. [Epub ahead of print]

Mandalà M, Barni S, Prins M, Labianca R, Tondini C, Russo L, Milesi A, Cremonesi M, Zaccanelli M, Regonesi C, Moro C, Falanga A
Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial.
Ann Oncol. 2010 Apr;21(4):871-6. Epub 2009 Aug 27.

McMillin GA, Melis R, Wilson A, Strong MB, Wanner NA, Vinik RG, Peters CL, Pendleton RC
Gene-Based Warfarin Dosing Compared With Standard of Care Practices in an Orthopedic Surgery Population: A Prospective, Parallel Cohort Study.
Ther Drug Monit 2010 Apr 8. [Epub ahead of print]

Melillo SN, Scanlon JV, Exter BP, Steinberg M, Jarvis CI.
Rivaroxaban for Thromboprophylaxis in Patients Undergoing Major Orthopedic Surgery (June) (CE).
Ann Pharmacother 2010 Apr 27. [Epub ahead of print]

Meschia JF, Merrill P, Soliman EZ, Howard VJ, Barrett KM, Zakai NA, Kleindorfer D, Safford M, Howard G.
Racial disparities in awareness and treatment of atrial fibrillation: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study.
Stroke 2010 Apr;41(4):581-7. Epub 2010 Feb 26.

Nieuwlaat R, Barker L, Kim YK, Haynes RB, Eikelboom JW, Yusuf S, Connolly SJ.
Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients.
Thromb Res 2010 Apr;125(4):e128-31. Epub 2009 Nov 22.

Nilsson KR Jr, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP, Kober L, Granger CB, Lewis EF, McMurray JJ, Califf RM, Velazquez EJ.
Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial.
Heart 2010 Apr 20. [Epub ahead of print]

Noble S, Pasi J.
Epidemiology and pathophysiology of cancer-associated thrombosis.
Br J Cancer. 2010 Apr 13;102 Suppl 1:S2-9.

On behalf of the CANBESURE Study Group, Kakkar VV, Balibrea JL, Martínez-González J, Prandoni P.
Extended prophylaxis with bemiparin for prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study.
J Thromb Haemost. 2010 Apr 30. [Epub ahead of print]

Prandoni P, Taher A.
Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial).
Expert Opin Pharmacother 2010;11(6):1035-7

Prystowsky EN, Camm J, Lip GY, Allessie M, Bergmann JF, Breithardt G, Brugada J, Crijns H, Ellinor PT, Mark D, Naccarelli G, Packer D, Tamargo J.
The Impact of New and Emerging Clinical Data on Treatment Strategies for Atrial Fibrillation.
J Cardiovasc Electrophysiol 2010 Apr 8. [Epub ahead of print]

Raaz U, Kaeberich A, Maegdefessel L, Buerke M, Busshardt M, Schubert S, Russ M, Plehn A, Ebelt H, Werdan K, Schlitt A
The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
Thromb Haemost. 2010;103(4):808-14

Raslan AM, Fields JD, Bhardwaj A.
Prophylaxis for venous thrombo-embolism in neurocritical care: a critical appraisal.
Neurocrit Care. 2010 Apr;12(2):297-309.

Rudd KM, Dier JG.
Comparison of two different models of anticoagulation management services with usual medical care.
Pharmacotherapy 2010 Apr;30(4):330-8.

Spiezia L, Rossetto V, Campello E, Gavasso S, Woodhams B, Tormene D, Simioni P.
Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis.
Thromb Haemost. 2010 Apr 29;103(6). [Epub ahead of print]

Stangier J, Rathgen K, Stähle H, Mazur D.
Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Clin Pharmacokinet 2010;49(4):259-68

Stein PD, Chenevert TL, Fowler SE, Goodman LR, Gottschalk A, Hales CA, Hull RD, Jablonski KA, Leeper KV Jr, Naidich DP, Sak DJ, Sostman HD, Tapson VF, Weg JG, Woodard PK; PIOPED III (Prospective Investigation of Pulmonary Embolism Diagnosis III) Investigators.
Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III).
Ann Intern Med. 2010 Apr 6;152(7):434-43, W142-3

Ten Cate-Hoek AJ, Ten Cate H, Tordoir J, Hamulyák K, Prins MH.
Individually tailored duration of elastic compression therapy in relation to incidence of the postthrombotic syndrome.
J Vasc Surg. 2010 Apr 10. [Epub ahead of print]

Tran H, Collecutt M, Whitehead S, Salem HH.
Prothrombin Complex Concentrates Used Alone in Urgent Reversal of Warfarin Anticoagulation.
Intern Med J. 2010 Apr 12. [Epub ahead of print]

Trkulja V, Kolundzic R.
Rivaroxaban vs Dabigatran for Thromboprophylaxis After Joint-replacement Surgery: Exploratory Indirect Comparison Based on Meta-analysis of Pivotal Clinical Trials.
Croat Med J 2010 Apr 15;51(2):113-23.

Wang YL, Wu D, Nguyen-Huynh MN, Zhou Y, Wang CX, Zhao XQ, Liao XL, Liu LP, Wang YJ; for The Prevention of Recurrences of Stroke Study in China (PRESS-China) Investigators.
Antithrombotic management of ischemic stroke and transient ischemic attack in China: A consecutive cross-sectional survey.
Clin Exp Pharmacol Physiol. 2010 Apr 26. [Epub ahead of print]

Weitz JI
Potential of new anticoagulants in patients with cancer.
Thromb Res. 2010;125 Suppl 2:S30-5

Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, Garcia DA, Ageno W, Hylek EM; Warped Consortium.
Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users.
J Thromb Haemost 2010 Apr;8(4):744-9.

Yang L, Ge W, Yu F, Zhu H.
Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement--a systematic review and meta analysis.
Thromb Res 2010 Apr;125(4):e159-66. Epub 2009 Nov 25.

Aguilar MI, Freeman WD.
Treatment of coagulopathy in intracranial hemorrhage.
Curr Treat Options Neurol. 2010;12(2):113-28.

Arepally G, Bauer KA, Bhatt DL, Merli GJ, Naccarelli GV, Carter RD, Karcher RB, Berry CA, Keaton KL, Stowell SA.
The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education.
Crit Pathw Cardiol 2010;9(1):41-8

Audebert HJ, Schenk B, Schenkel J, Heuschmann PU.
Impact of prestroke oral anticoagulation on severity and outcome of ischemic and hemorrhagic stroke in patients with atrial fibrillation.
Cerebrovasc Dis 2010;29(5):476-483

Benmira S, Banda ZK, Bhattacharya V.
Old Versus New Anticoagulants: Focus on Pharmacology.
Recent Pat Cardiovasc Drug Discov 2010 Mar 26 [Epub ahead of print]

Clayton RA, Gaston P, Howie CR.
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
J Bone Joint Surg Br 2010;92(3):468

Colwell CW Jr, Froimson MI, Mont MA, Ritter MA, Trousdale RT, Buehler KC, Spitzer A, Donaldson TK, Padgett DE.
Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low-molecular-weight heparin.
J Bone Joint Surg Am 2010;92(3):527-35

Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, Prisco D, Poli D, Tripodi A, Palareti G; for the PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics).
Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the prolong study.
Thromb Haemost 2010 Mar 29;103(6). [Epub ahead of print]

Douma RA, Kok MG, Verberne LM, Kamphuisen PW, Büller HR.
Incidental venous thromboembolism in cancer patients: prevalence and consequence.
Thromb Res 2010 Mar 9. [Epub ahead of print]

Douma RA, le Gal G, Söhne M, Righini M, Kamphuisen PW, Perrier A, Kruip MJ, Bounameaux H, Büller HR, Roy PM.
Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts.
BMJ. 2010 Mar 30;340:c1475. doi: 10.1136/bmj.c1475.

Eikelboom JW, O'Donnell M, Yusuf S, Diaz R, Flaker G, Hart R, Hohnloser S, Joyner C, Lawrence J, Pais P, Pogue J, Synhorst D, Connolly SJ.
Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
Am Heart J 2010;159(3):348-353.e1

Fareed J, Hull R.
Apixaban to prevent venous thromboembolism after knee replacement.
Lancet 2010;375(9717):779-80.

Folsom AR, Lutsey PL, Astor BC, Wattanakit K, Heckbert SR, Cushman M; for the Atherosclerosis Risk in Communities (ARIC) Study.
Chronic kidney disease and venous thromboembolism: a prospective study.
Nephrol Dial Transplant 2010 Mar 29. [Epub ahead of print]

Gao F, Zhou YJ, Wang ZJ, Shen H, Liu XL, Nie B, Yan ZX, Yang SW, Jia de A, Yu M.
Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation.
Circ J 2010 Mar 25;74(4):701-8. Epub 2010 Mar 6.

Hankey GJ, Eikelboom JW.
Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events.
Lancet Neurol 2010;9(3):273-284

Kristinsson SY, Pfeiffer RM, Björkholm M, Goldin LR, Schulman S, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O.
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.
Blood 2010 Mar 18. [Epub ahead of print]

Labropoulos N, Jen J, Jen H, Gasparis AP, Tassiopoulos AK.
Recurrent deep vein thrombosis: Long-term incidence and natural history.
Ann Surg 2010 Mar 10. [Epub ahead of print]

Lankeit M, Konstantinides S.
Thrombolysis for pulmonary embolism: Past, present and future.
Thromb Haemost. 2010 Mar 9;103(5). [Epub ahead of print]

Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators.
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Lancet 2010;375(9717):807-15

Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L; on behalf of the ARISTOTLE Investigators.
Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: Design and rationale.
Am Heart J 2010;159(3):331-339

Mackman N, Becker RC
DVT: a new era in anticoagulant therapy.
Arterioscler Thromb Vasc Biol. 2010;30(3):369-71

Maleux G, Marchal P, Palmers M, Heye S, Verhamme P, Vaninbroukx J, Verhaeghe R.
Catheter-directed thrombolytic therapy for thoracic deep vein thrombosis is safe and effective in selected patients with and without cancer.
Eur Radiol. 2010 Mar 28. [Epub ahead of print]

Mazzaglia G, Filippi A, Alacqua M, Cowell W, Shakespeare A, Mantovani LG, Bianchi C, Cricelli C.
A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care.
Thromb Haemost 2010;103(5). [Epub ahead of print]

Olsson SB, Rasmussen LH, Tveit A, Jensen E, Wessman P, Panfilov S, Wåhlander K.
Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Thromb Haemost. 2010;103(3):604-12

Palaniswamy C, Selvaraj DR.
Periprocedural bridging anticoagulation: Current perspectives.
Am J Ther 2010 Mar 11 [Epub ahead of print]

Perez A, Bartholomew JR
Interpreting the JUPITER trial: statins can prevent VTE, but more study is needed.
Cleve Clin J Med 2010;77(3):191-4

Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY.
A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey.
Chest 2010 Mar 18. [Epub ahead of print]

Pisters R, van Oostenbrugge RJ, Knottnerus IL, de Vos CB, Boreas A, Lodder J, Prins MH, Crijns HJ, Tieleman RG.
The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines.
Europace. 2010 Mar 26. [Epub ahead of print]

Rowe AS, Turner RM.
Coagulation factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage.
Am J Health Syst Pharm 2010 Mar 1;67(5):361-5

Sheehan OC, Kyne L, Kelly LA, Hannon N, Marnane M, Merwick A, McCormack PM, Duggan J, Moore A, Moroney J, Daly L, Harris D, Horgan G, Williams EB, Kelly PJ.
Population-based study of ABCD2 score, carotid stenosis, and atrial fibrillation for early stroke prediction after transient ischemic attack: The North Dublin TIA study.
Stroke 2010 Mar 18. [Epub ahead of print]

Teachey DT.
Dabigatran versus warfarin for venous thromboembolism.
N Engl J Med 2010;362(11):1050

The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators.
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: Rationale and design of the ROCKET AF study.
Am Heart J 2010;159(3):340-347

Tulner LR, Kuper IM, van Campen JP, MacGillavry MR, Kwa VI, Koks CH, Beijnen JH, Brandjes DP.
Contraindications for anticoagulation in older patients with atrial fibrillation: A narrative review.
Curr Drug Saf 2010 Mar 7. [Epub ahead of print]

Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A.
Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity.
Thromb Haemost 2010 Mar 29;103(6). [Epub ahead of print]

Vavra KA, Lutz MF, Smythe MA
Recombinant Factor VIIa to manage major bleeding from newer parenteral anticoagulants.
Ann Pharmacother. 2010;44(4):718-26

Verheugt FW.
Novel oral anticoagulants to prevent stroke in atrial fibrillation.
Nat Rev Cardiol 2010;7(3):149-54

Agarwal S, Bennett D, Smith DJ.
Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
Am J Cardiovasc Drugs. 2010;10(1):37-48.

Armaganijan L, Eikelboom J, Healey JS, Morillo CA.
New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010.1.
Adv Ther 2009;26(12):1058-71. Epub 2010 Feb 1.

Bauersachs RM, Riess H, Hach-Wunderle V, Gerlach H, Carnarius H, Eberle S, Rabe E, Schellong S.
Impact of gender on the clinical presentation and diagnosis of deep-vein thrombosis.
Thromb Haemost 2010 Feb 19;103(4). [Epub ahead of print]

Budhraja V.
The net clinical benefit of warfarin anticoagulation in atrial fibrillation.
Ann Intern Med 2010;152(4):265

Bussey H.
The net clinical benefit of warfarin anticoagulation in atrial fibrillation.
Ann Intern Med 2010;152(4):264-5

Chamorro A.
Dual antiplatelet therapy is not optimal for stroke prevention in patients with atrial fibrillation.
Int J Stroke. 2010 Feb;5(1):28-9.

Clark P, Wu O, Greer IA, Lowe GD.
Venous thrombosis prevention - more than just guidelines.
Br J Haematol 2010 Feb 8. [Epub ahead of print]

Cohen M.
The thrombin hypothesis in ACS: a disappointing disconnect between bench data and bedside clinical trials.
Am J Med 2010;123(2):103-10

Cook DJ, Crowther MA.
Thromboprophylaxis in the intensive care unit: focus on medical-surgical patients.
Crit Care Med. 2010 Feb;38(2 Suppl):S76-82.

Debergh I, Van Damme N, Pattyn P, Peeters M, Ceelen WP.
The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model.
Br J Cancer 2010 Feb 2. [Epub ahead of print]

Decousus H, Quéré I, Presles E, Becker F, Barrellier MT, Chanut M, Gillet JL, Guenneguez H, Leandri C, Mismetti P, Pichot O, Leizorovicz A for the POST (Prospective Observational Superficial Thrombophlebitis) Study Group.
Superficial venous thrombosis and venous thromboembolism: A large, prospective epidemiologic study.
Ann Intern Med 2010;152(4):218-224

Dentali F, Crowther M.
Antiphospholipid antibodies in critical illness.
Crit Care Med 2010 Feb;38(2 Suppl):S51-6.

Di Nisio M, van Sluis GL, Bossuyt PM, Büller HR, Porreca E, Rutjes AW.
Accuracy of diagnostic tests for clinically suspected upper extremity deep vein thrombosis: a systematic review.
J Thromb Haemost 2010 Feb 6. [Epub ahead of print]

Eikelboom JW, Wallentin L, Yusuf S, Ezekowitz MD, Reilly PA, Brueckmann M, Clemens A, Connolly SJ.
Does dabigatran improve stroke-prevention in atrial fibrillation?
J Thromb Haemost 2010 Feb 9. [Epub ahead of print]

Eikelboom JW, Zelenkofske SL, Rusconi CP.
Coagulation Factor IXa as a target for treatment and prophylaxis of venous thromboembolism.
Arterioscler Thromb Vasc Biol 2010;30(3):382-7. [Epub 2010 Feb 5]

Gorin L, Fauchier L, Nonin E, de Labriolle A, Haguenoer K, Cosnay P, Babuty D, Charbonnier B.
Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1.
Thromb Haemost 2010 Feb 2;103(3). [Epub ahead of print]

Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P.
Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome.
Atheroscler Thromb 2010 Feb 3. [Epub ahead of print]

Hankey GJ.
Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
Curr Opin Neurol. 2010 Feb;23(1):65-72.

Jaffer AK, Brotman DJ, Bash LD, Mahmood SK, Lott B, White RH.
Variations in perioperative warfarin management: outcomes and practice patterns at nine hospitals.
Am J Med 2010;123(2):141-50

Lopes RD, Starr A, Pieper CF, Al-Khatib SM, Newby LK, Mehta RH, Van de Werf F, Mahaffey KW, Armstrong PW, Harrington RA, White HD, Wallentin L, Granger CB.
Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes.
Am J Med. 2010 Feb;123(2):134-40.

Mahan CE, Pini M, Spyropoulos AC.
Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosing.
Intern Emerg Med 2010 Feb 23. [Epub ahead of print]

Maynard G, Stein J.
Designing and implementing effective venous thromboembolism prevention protocols: lessons from collaborative efforts.
J Thromb Thrombolysis. 2010 Feb;29(2):159-66.

McBane RD, Wysokinski WE, Daniels PR, Litin SC, Slusser J, Hodge DO, Dowling NF, Heit JA.
Periprocedural anticoagulation management of patients with venous thromboembolism.
Arterioscler Thromb Vasc Biol 2010;30(3):442-8. [Epub 2010 Feb 5.]

Mismetti P, Baud JM, Becker F, Belmahdi F, Blanchard P, Constans J, Couturaud F, Debourdeau P, Drouet L, Dumarcet N, Ferrari E, Galanaud JP, Girard P, Hay B, Laporte S, Laroche JP, Leizorovicz A, Liard F, Mahe I, Meyer G, Oger E, Parent F, Quere I, Samama M.
Guidelines for good clinical practice: Prevention and treatment of venous thromboembolism in medical patients.
J Mal Vasc 2010 Feb 15. [Epub ahead of print]

Morell J, Sullivan B, Khalabuda M, McBride BF.
Role of orally available antagonists of Factor Xa in the treatment and prevention of thromboembolic disease: Focus on rivaroxaban.
J Clin Pharmacol 2010 Feb 2. [Epub ahead of print]

Niki Y, Matsumoto H, Hakozaki A, Mochizuki T, Momohara S
Rheumatoid arthritis: a risk factor for deep venous thrombosis after total knee arthroplasty? Comparative study with osteoarthritis.
J Orthop Sci. 2010;15(1):57-63

Ntep-Gweth M, Zimmermann M, Meiltz A, Kingue S, Ndobo P, Urban P, Bloch A.
Atrial fibrillation in Africa: clinical characteristics, prognosis, and adherence to guidelines in Cameroon.
Europace 2010 Feb 23. [Epub ahead of print]

Paulson R.
Implementing deep vein thrombosis prophylaxis in hospital patients: another option.
Am J Med. 2010 Feb;123(2):e13; author reply e15.

Pendergrast J.
Urgent warfarin reversal: know your options.
Can J Anaesth 2010 Feb 23. [Epub ahead of print]

Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V.
Rivaroxaban: a new oral factor Xa inhibitor.
Arterioscler Thromb Vasc Biol 2010 Mar;30(3):376-81. [Epub 2010 Feb 5.]

Poli D, Grifoni E, Antonucci E, Arcangeli C, Prisco D, Abbate R, Miniati M.
Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension in patients after a first episode of pulmonary embolism.
J Thromb Thrombolysis 2010 Feb 16. [Epub ahead of print]

Quan ML, Pinto DJ, Rossi KA, Sheriff S, Alexander RS, Amparo E, Kish K, Knabb RM, Luettgen JM, Morin P, Smallwood A, Woerner FJ, Wexler RR
Phenyltriazolinones as potent Factor Xa inhibitors.
Bioorg Med Chem Lett. 2010;20(4):1373-7

Samama MM, Martinoli JL, Leflem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E.
Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor.
Thromb Haemost 2010 Feb 2;103(4). [Epub ahead of print]

Sansone JM, del Rio AM, Anderson PA.
The prevalence of and specific risk factors for venous thromboembolic disease following elective spine surgery.
J Bone Joint Surg Am 2010;92(2):304-13

Schwammenthal Y, Bornstein N, Schwammenthal E, Schwartz R, Goldbourt U, Tsabari R, Koton S, Grossman E, Tanne D.
Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]).
Am J Cardiol. 2010 Feb 1;105(3):411-6. Epub 2009 Dec 22.

Sharma T, Mehta P, Gajra A.
Update on fondaparinux: Role in management of thromboembolic and acute coronary events.
Cardiovasc Hematol Agents Med Chem 2010 Feb 25. [Epub ahead of print]

Taimeh Z, Weksler B.
Review: recent advances in argatroban-warfarin transition in patients with heparin-induced thrombocytopenia.
Clin Appl Thromb Hemost. 2010 Feb;16(1):5-12. Epub 2008 Dec 2.

Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Zado E, Rossillo A, Di Biase L, Schweikert RA, Saliba WI, Horton R, Mohanty P, Patel D, Burkhardt DJ, Wazni OM, Bonso A, Callans DJ, Haissaguerre M, Raviele A, Natale A.
The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation.
J Am Coll Cardiol 2010;55(8):735-743

Ufer M.
Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
Thromb Haemost 2010 Feb 2;103(3). [Epub ahead of print]

Vedovati MC, Becattini C, Agnelli G.
Combined oral anticoagulants and antiplatelets: benefits and risks.
Intern Emerg Med 2010 Feb 11. [Epub ahead of print]

Albers GW.
Stroke: more protection for patients with atrial fibrillation.
Lancet Neurol. 2010 Jan;9(1):2-4.

Bauersachs RM, Haas S.
Prophylaxis for thromboembolism in internal medicine and family practice.
Internist (Berl) 2010 Jan 28. [Epub ahead of print]

Blackshear RH, Crosson KC.
Reduction in Pulmonary Embolism after Total Joint Arthroplasty: Three Years of Experience with Extended-Release Epidural Morphine.
Pain Pract. 2010 Jan 8. [Epub ahead of print]

Callejas Rubio JL, Lara Jiménez MA, Fernández Pugnaire MA, Ortego Centeno N.
Dabigatran in the treatment of a morbidly obese patient with recurring venous thrombosis.
Farm Hosp 2010;34(2):101

Caprini JA.
Risk assessment as a guide for the prevention of the many faces of venous thromboembolism.
Am J Surg 2010;199(1 Suppl):S3-10

Castelli R, Ferrari B, Cortelezzi A, Guariglia A.
Thromboembolic Complications in Malignant Haematological Disorders.
Curr Vasc Pharmacol. 2010 Jan 1. [Epub ahead of print]

Cha SI, Lee SY, Kim CH, Park JY, Jung TH, Yi JH, Lee J, Huh S, Lee HJ, Kim SY.
Venous thromboembolism in Korean patients undergoing major orthopedic surgery: a prospective observational study using computed tomographic (CT) pulmonary angiography and indirect CT venography.
J Korean Med Sci. 2010 Jan;25(1):28-34.

Chong BH, Chong JJ
Heparin-induced thrombocytopenia associated with fondaparinux.
Clin Adv Hematol Oncol 2010;8(1):63-5

De Bono J, Nazir S, Ruparelia N, Bashir Y, Betts T, Rajappan K.
Perioperative management of anticoagulation during device implantation-The UK perspective.
Pacing Clin Electrophysiol 2010 Jan 27. [Epub ahead of print]

Eikelboom JW, Weitz JI.
Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?
Thromb Haemost. 2010 Jan 13;103. [Epub ahead of print]

Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Wetherill G, Wilpshaar JW, Meems L; for the ONYX-2 study group.
Prevention of venous thromboembolism with an oral Factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
J Thromb Haemost. 2010 Jan 17. [Epub ahead of print]

Gassanov N, Caglayan E, Erdmann E, Er F.
Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases?
Dtsch Med Wochenschr. 2010 Jan 26. [Epub ahead of print]

Hannon N, Sheehan O, Kelly L, Marnane M, Merwick A, Moore A, Kyne L, Duggan J,Moroney J, McCormack PM, Daly L, Fitz-Simon N, Harris D, Horgan G, Williams EB, Furie KL, Kelly PJ.
Stroke associated with atrial fibrillation--incidence and early outcomes in the north dublin population stroke study.
Cerebrovasc Dis. 2010;29(1):43-9. Epub 2009 Nov 5.

Jiang J, Hu Y, Zhang J, Yang J, Mueck W, Kubitza D, Bauer RJ, Meng L, Hu P.
Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects.
Thromb Haemost. 2010 Jan;103(1):234-41.

Jimenez D, Aujesky D, Diaz G, Monreal M, Otero R, Marti D, Marin E, Aracil E, Sueiro A, Yusen RD, The Riete Investigators.
Prognostic Significance of Deep Vein Thrombosis in Patients Presenting with Acute Symptomatic Pulmonary Embolism.
Am J Respir Crit Care Med. 2010 Jan 28. [Epub ahead of print]

Kaatz S, Douketis JD, Zhou H, Gage BF, White RH.
Risk of stroke after surgery in patients with and without chronic atrial fibrillation.
J Thromb Haemost. 2010 Jan 24. [Epub ahead of print]

Kerr J, Linkins LA.
High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxis.
Thromb Haemost. 2010 Jan;103(1):123-8. Epub 2009 Oct 26.

Khoo CW, Lip GY.
Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial.
Expert Opin Pharmacother. 2010 Jan 28. [Epub ahead of print]

Lane DA, Lip GY.
Anticoagulation intensity for elderly atrial fibrillation patients: Should we use a conventional INR target (2.0 to 3.0) or a lower range?
Thromb Haemost. 2010 Jan 13;103. [Epub ahead of print]

Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marín F.
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting.
Thromb Haemost 2010 Jan;103(1):13-28. Epub 2009 Sep 30.

McAndrew CM, Fitzgerald SJ, Kraay MJ, Goldberg VM.
Incidence of postthrombotic syndrome in patients undergoing primary total knee arthroplasty for osteoarthritis.
Clin Orthop Relat Res 2010 Jan;468(1):178-81. Epub 2009 Jun 19.

Muntz JE, Michota FA.
Prevention and management of venous thromboembolism in the surgical patient: options by surgery type and individual patient risk factors.
Am J Surg 2010 Jan;199(1 Suppl):S11-20

Neviaser AS, Chang C, Lyman S, Della Valle AG, Haas SB.
High incidence of complications from enoxaparin treatment after arthroplasty.
Clin Orthop Relat Res. 2010 Jan;468(1):115-9. Epub 2009 Aug 11.

Owen A.
Antithrombotic treatment for the primary prevention of stroke in patients with non valvular atrial fibrillation: A reappraisal of the evidence and network meta analysis.
Int J Cardiol. 2010 Jan 8. [Epub ahead of print]

Palareti G, Cosmi B.
Emerging drugs for venous thromboembolism.
Expert Opin Emerg Drugs. 2010 Jan 15. [Epub ahead of print]

Paty I, Trellu M, Destors JM, Cortez P, Boëlle E, Sanderink G.
Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion.
J Thromb Haemost. 2010 Jan 17. [Epub ahead of print]

Pengo V, Cucchini U, Denas G, Davidson BL, Marzot F, Padayattil Jose S, Iliceto S.
Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation.
Thromb Haemost. 2010 Jan 13;103. [Epub ahead of print]

Rhodes DA, Severson EP, Hodrick JT, Dunn HK, Hofmann AA.
Discontinuation of warfarin is unnecessary in total knee arthroplasty.
Clin Orthop Relat Res. 2010;468:120-6.

Robert F.
The potential benefits of low-molecular-weight heparins in cancer patients.
J Hematol Oncol. 2010 Jan 14;3(1):3. [Epub ahead of print]

Robert-Ebadi H, Le Gal G, Carrier M, Couturaud F, Perrier A, Bounameaux H, Righini M.
Differences in clinical presentation of pulmonary embolism in women and men.
J Thromb Haemost. 2010 Jan 22. [Epub ahead of print]

Schulman S, Spencer FA.
Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding.
J Thromb Haemost. 2010 Jan 6. [Epub ahead of print]

Spinler SA.
Atrial fibrillation: A promising new anticoagulant for stroke prevention.
Nat Rev Cardiol 2010;7(1):10-1

Tulner LR, Van Campen JP, Kuper IM, Gijsen GJ, Koks CH, Mac Gillavry MR, van Tinteren H, Beijnen JH, Brandjes DP.
Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study.
Drugs Aging. 2010;27(1):39-50.

Willeke A, Lindhoff-Last E
Treatment of venous thromboembolism.
Internist (Berl). 2010;51(3):335-6, 338-43

Yong CM, Boyle AJ.
Factor Xa Inhibitors in Acute Coronary Syndromes and Venous Thromboembolism.
Curr Vasc Pharmacol. 2010 Jan 1. [Epub ahead of print]

Castellone DD, Van Cott EM.
Laboratory monitoring of new anticoagulants.
Am J Hematol 2009;85(3):185-187. [Epub ahead of print]

Cohen AT.
Prevention of postoperative venous thromboembolism.
BMJ. 2009 Dec 3;339:b4477. (Comment on: Sweetland et al)

Colwell CW.
The ACCP guidelines for thromboprophylaxis in total hip and knee arthroplasty.
Orthopedics 2009;32(12 Suppl):67-73

Dentali F, Ageno W.
Cerebral vein thrombosis.
Intern Emerg Med. 2009 Dec 1. [Epub ahead of print]

Friedman RJ.
New oral anticoagulants for thromboprophylaxis after total hip or knee arthroplasty.
Orthopedics 2009;32(12 Suppl):79-84

Guédon-Moreau L, Kacet S.
Atrial fibrillation: challenge of antithrombotic treatment.
Ann Cardiol Angeiol (Paris). 2009 Dec;58 Suppl 1:S25-30

Hankey GJ.
At last, a RE-LYable alternative to warfarin for atrial fibrillation.
Int J Stroke. 2009 Dec;4(6):454-5.

Hellmann I, Ellis MH.
Prevention of venous thromboembolism in medical patients: recent advances and future directions.
Isr Med Assoc J 2009;11(12):753-7

Imberti D, Dall'Asta C, Pierfranceschi MG.
Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review.
Intern Emerg Med. 2009 Dec;4(6):471-7.

Ji JH, Shafi M, Sung JH, Moon CY, Park SE, Lee YS.
Thromboembolic complications after bilateral knee arthroscopic surgery patients.
Knee Surg Sports Traumatol Arthrosc. 2009 Dec 24. [Epub ahead of print]

Klok FA, Zondag W, van Kralingen KW, van Dijk AP, Tamsma JT, Heyning FH, Vliegen HW, Huisman MV.
Patient Outcomes After Acute Pulmonary Embolism: a Pooled Survival Analysis of Different Adverse Events.
Am J Respir Crit Care Med. 2009 Dec 3. [Epub ahead of print]

Lachiewicz PF.
Comparison of ACCP and AAOS guidelines for VTE prophylaxis after total hip and total knee arthroplasty.
Orthopedics 2009;32(12 Suppl):74-8

Lafuente-Lafuente C, Mahé I, Extramiana F.
Management of atrial fibrillation.
BMJ. 2009 Dec 23;339:b5216

Lee BH, Park JS, Park JH, Park JS, Kwak JJ, Hwang ES, Kim SK, Choi DH, Kim YH, Pak HN.
The Effect and Safety of the Antithrombotic Therapies in Patients with Atrial Fibrillation and CHADS Score 1.
J Cardiovasc Electrophysiol. 2009 Dec 15. [Epub ahead of print]

Marmur JD, Bullock-Palmer RP, Poludasu S, Cavusoglu E.
Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention
J Invasive Cardiol. 2009 Dec;21(12):653-64.

Massoure PL, Sacher F, Derval N, Hocini M, Jais P, Haissaguerre M.
Atrial fibrillation in elderly patients.
Rev Prat. 2009 Dec 20;59(10):1365-9.[Article in French]

Ramacciotti E, Myers DD Jr, Wrobleski SK, Deatrick KB, Londy FJ, Rectenwald JE, Henke PK, Schaub RG, Wakefield TW.
P-selectin/ PSGL-1 Inhibitors versus enoxaparin in the resolution of venous thrombosis: A meta-analysis.
Thromb Res. 2009 Dec 3. [Epub ahead of print]

Rose AJ, Ozonoff A, Henault LE, Hylek EM.
Anticoagulation for valvular heart disease in community-based practice.
Thromb Haemost. 2009 Dec 18. [Epub ahead of print]

Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; the RE-COVER Study Group.
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
N Engl J Med. 2009 Dec 6. [Epub ahead of print]

Siller-Matula JM, Krumphuber J, Jilma B.
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.
Br J Pharmacol. 2009 Dec 24. [Epub ahead of print]

Sweetland S, Green J, Liu B, Berrington de González A, Canonico M, Reeves G, Beral V; Million Women Study collaborators.
Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study.
BMJ. 2009 Dec 3;339:b4583.

Warwick D, Rosencher N.
The "Critical Thrombosis Period" in Major Orthopedic Surgery: When to Start and When to Stop Prophylaxis.
Clin Appl Thromb Hemost. 2009 Dec 16. [Epub ahead of print]

Weber KL, Zuckerman JD, Watters WC 3rd, Turkelson CM.
Deep vein thrombosis prophylaxis.
Chest. 2009 Dec;136(6):1699-700.

Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Noack H, Robinson PA, Dolan G, Brenkel IJ.
Economic evaluation of dabigatran etexilate for the preventionof venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
Thromb Haemost. 2009 Dec 18. [Epub ahead of print]

Zikria J, Ansell J.
Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin?
Discov Med. 2009 Dec;8(43):196-203.

Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M; on behalf of the PROTECHT Investigators.
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.
Lancet Oncol. 2009 Nov;39(11):752-6.

Ahmad O, Ahmad KE, Dear KB, Harvey I, Hughes A, Lueck CJ.
Atrial Fibrillation and Anticoagulation in a Stroke Unit Population.
Intern Med J. 2009 Nov;39(11):752-6.

Apostolakis S, Shantsila E, Lip GY, Lane DA.
Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
Thromb Haemost. 2009 Nov;102(5):914-5.

Aujesky D, Mazzolai L, Hugli O, Perrier A.
Outpatient treatment of pulmonary embolism.
Swiss Med Wkly 2009;139(47-48):685-90

Bellamy L, Rosencher N, Eriksson B.
Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate.
Patient Prefer Adherence. 2009 Nov 3;3:173-177.

Capri S, Ageno W, Imberti D, Palareti G, Piovella F, Scannapieco G, Moia M.
Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis.
Intern Emerg Med. 2009 Nov 5. [Epub ahead of print]

Donadini MP, Douketis JD.
Combined warfarin-aspirin therapy: what is the evidence for benefit and harm and which patients should (and should not) receive it?
J Thromb Thrombolysis. 2009 Nov 15. [Epub ahead of print]

Ehrlich JR, Hohnloser SH.
Milestones in the management of atrial fibrillation.
Heart Rhythm. 2009 Nov;6(11 Suppl):S62-7. Epub 2009 Sep 1.

Eikelboom JW, Quinlan DJ, O'Donnell M.
Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials.
Circulation. 2009 Nov 17;120(20):2006-11. Epub 2009 Nov 2.

Eischer L, Eichinger S, Kyrle PA.
Age at first venous thromboembolism and risk of recurrence: a prospective cohort study.
Medicine (Baltimore). 2009 Nov;88(6):366-70.

Fassiadis N.
Rivaroxaban, the first oral, direct factor Xa inhibitor.
Expert Opin Pharmacother. 2009 Nov 19. [Epub ahead of print]

Gómez-Outes A, Suárez-Gea ML, Pozo-Hernández C, Lassen MR, Raskob GE, Gallus A.
Apixaban or Enoxaparin for Thromboprophylaxis.
N Engl J Med. 2009 Nov 19;361(21):2100-2101.

Hammerstingl C, Schmitz A, Fimmers R, Omran H.
Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry.
Cardiovasc Ther. 2009 Winter;27(4):230-8.

Hankey GJ.
Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
Curr Opin Neurol. 2009 Nov 25. [Epub ahead of print]

Harenberg J.
Development of idraparinux and idrabiotaparinux for anticoagulant therapy.
Thromb Haemost. 2009 Nov;102(5):811-5.

Healey JS. Pro
Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation
Thromb Haemost 2009 Nov;102(5):912-3.

Hörl WH.
Oral anticoagulation with coumarins for patients with atrial fibrillation and chronic kidney disease?
Wien Klin Wochenschr. 2009;121(21-22):668-72.

Jaffer AK.
Perioperative management of warfarin and antiplatelet therapy.
Cleve Clin J Med. 2009 Nov;76 Suppl 4:S37-44.

Laux V, Perzborn E, Heitmeier S, von Degenfeld G, Dittrich-Wengenroth E, Buchmüller A, Gerdes C, Misselwitz F.
Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
Thromb Haemost. 2009 Nov;102(5):892-9.

Lu JP, Knudson MM, Bir N, Kallet R, Atkinson K.
Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: a pilot study.
J Am Coll Surg. 2009 Nov;209(5):589-94. 2009 Nov;209(5):589-94. Epub 2009 Sep 11.

No authors listed
HOTLINE I, RE-LY, diabigatran gains ground on warfarin.
Eur Heart J 2009 Nov;30(21):2542.

Piazza G, Goldhaber SZ.
Physician alerts to prevent venous thromboembolism.
J Thromb Thrombolysis. 2009 Nov 4. [Epub ahead of print]

Romera-Villegas A, Cairols-Castellote MA, Vila-Coll R, Martí-Mestre X, Colomé E, Iguaz I.
Long-Term Use of Different Doses of Low-Molecular-Weight Heparin Versus Vitamin K Antagonists in the Treatment of Venous Thromboembolism
.Ann Vasc Surg. 2009 Nov 23. [Epub ahead of print]

Sun JM, Kim TS, Lee J, Park YH, Ahn JS, Kim H, Kwon OJ, Lee KS, Park K, Ahn MJ.
Unsuspected pulmonary emboli in lung cancer patients: The impact on survival and the significance of anticoagulation therapy.
Lung Cancer [Epub ahead of print]

Sutedjo JL, Ng RK, Piazza G, Goldhaber SZ.
Medicare's new regulations for deep vein thrombosis as a "never event": wise or worrisome?
Am J Med. 2009 Nov;122(11):975-6.

Wittkowsky AK.
New oral anticoagulants: a practical guide for clinicians.
J Thromb Thrombolysis. 2009 Nov 4. [Epub ahead of print]

Apostolakis S, Shantsila E, Lip GY.
New anticoagulants for the prevention of deep venous thrombosis: time to consider cost effectiveness?
Pharmacoeconomics. 2009;27(10):793-5.

Collet JP, Aout M, Alantar A, Coriat P, Napoléon B, Thomas D, Trosini-Desert V, Tucas G, Vicaut E, Montalescot G.
Real-life management of dual antiplatelet therapy interruption: the REGINA survey.
Arch Cardiovasc Dis. 2009 Oct;102(10):697-710. Epub 2009 Oct 27.

Collins DR.
No longer need to RE-LY on Warfarin for stroke prevention?
Ir Med J. 2009 Oct;102(9):278-9.

Dagres N, Hindricks G, Kottkamp H, Sommer P, Gaspar T, Bode K, Arya A, Rallidis LS, Kremastinos DT, Piorkowski C.
Real-life anticoagulation treatment of atrial fibrillation after catheter ablation: Possible overtreatment of low-risk patients.
Thromb Haemost. 2009;102(4):754-8.

De A, Roy P, Garg VK, Pandey NK.
Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery
Blood Coagul Fibrinolysis. 2009 Oct 19. [Epub ahead of print]

Dunn A.
Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrillation.
Evid Based Med. 2009;14(5):140.

Fanikos J, Piazza G, Zayaruzny M, Goldhaber SZ.
Long-term complications of medical patients with hospital-acquired venous thromboembolism.
Thromb Haemost. 2009;102(4):688-93.

Farge D, Bosquet L, Kassab-Chahmi D, Mismetti P, Elalamy I, Meyer G, Cajfinger F, Desmurs-Clavel H, Elias A, Grange C, Hocini H, Legal G, Mahe I, Quéré I, Levesque H, Debourdeau P.
2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: Report from the working group.
Crit Rev Oncol Hematol. 2009 Oct 2. [Epub ahead of print]

Fuji T, Fuijita S, Ujihira T, Sato T
Dabigatran Etexilate Prevents Venous Thromboembolism After Total Knee Arthroplasty in Japanese Patients, With a Safety Profile Comparable to Placebo.
J Arthroplasty 2009 Oct 24. [Epub ahead of print]

Garcia D, Libby E, Crowther MA.
The new oral anticoagulants.
Blood. 2009 Oct 30. [Epub ahead of print]

Griffiths GO, Burns S, Noble SI, Macbeth FR, Cohen D, Maughan TS.
FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer.
BMC Cancer. 2009;9:355.

Grouzi E, Kyriakou E, Panagou I, Spiliotopoulou I.
Fondaparinux for the Treatment of Acute Heparin-Induced Thrombocytopenia: A Single-Center Experience.
Clin Appl Thromb Hemost. 2009 Oct 13. [Epub ahead of print]

Heindl B, Spannagl M.
New oral anticoagulants : Consequences for perioperative coagulation diagnostics and therapy.
Anaesthesist. 2009 Oct 14. [Epub ahead of print] German.

Kohsaka S, Homma S.
Anticoagulation for heart failure: selecting the best therapy.
Expert Rev Cardiovasc Ther. 2009;7(10):1209-17.

Kucher N, Spirk D, Baumgartner I, Mazzolai L, Korte W, Nobel D, Banyai M, Bounameaux H.
Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER).
Ann Oncol. 2009 Oct 14. [Epub ahead of print]

Liakishev AA.
Dabigatran versus Warfarin in Patients with Atrial Fibrillation. Results of the RE-LY study.
Kardiologiia. 2009;49(10):75-6.

Lyman GH.
Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer.
Cancer. 2009 Oct 13. [Epub ahead of print]

Malato A, Saccullo G, Coco LL, Caramazza D, Abbene I, Pizzo G, Casuccio A, Siragusa S.
Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular weight heparin.
J Thromb Haemost. 2009 Oct 11. [Epub ahead of print]

Markel DC, York S, Liston MJ Jr, Flynn JC, Barnes CL, Davis CM 3rd; the AAHKS Research Committee.
Venous Thromboembolism Management by American Association of Hip and Knee Surgeons.
J Arthroplasty. 2009 Oct 16. [Epub ahead of print]

No authors listed
Dabigatran: safer, more effective and easier to use than warfarin.
Cardiovasc J Afr. 2009 Sep-Oct;20(5):311-3.

Palla A, Ribas C, Rossi G, Pepe P, Marconi L, Prandoni P.
The clinical course of 1-year anticoagulated pulmonary embolism: results of a prospective, observational, cohort study.
J Thromb Haemost. 2009 Oct 10. [Epub ahead of print]

Samama MM, Gerotziafas GT.
Newer anticoagulants in 2009.
J Thromb Thrombolysis. 2009 Oct 17. [Epub ahead of print]

Sood MM, Komenda P, Sood AR, Rigatto C, Bueti J.
The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis?
Chest. 2009;136(4):1128-33.

Stein PD, Hull RD, Matta F, Yaekoub AY.
Anticoagulants for Acute Venous Thromboembolism: What We Think We Know and What the Data Show for Timing of Recurrent Events.
Clin Appl Thromb Hemost. 2009 Oct 13. [Epub ahead of print]

Stein PD, Hull RD, Matta F, Yaekoub AY.
Early Discharge of Patients With Venous Thromboembolism: Implications Regarding Therapy.
Clin Appl Thromb Hemost. 2009 Oct 14. [Epub ahead of print]

Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.
Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Health Technol Assess. 2009 Oct;13 Suppl 3:43-8.

Vardi M, Zittan E, Bitterman H.
Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Cochrane Database Syst Rev. 2009;(4):CD006771.

Weimar C, Weber R, Diener HC.
Antithrombotic medication for stroke prevention.
Expert Rev Cardiovasc Ther. 2009;7(10):1245-54.

Yuet Wan
Anticoagulation with dabigatran or rivaroxaban.
Drug Ther Bull. 2009;47(10):116-20.

[No authors listed]
Is dabigatran the ideal drug against thrombosis? Commentary to RE-LY.
Kardiol Pol 2009;67(10):1153-4

[No authors listed]
Dabigatran is better than warfarin in patients with atrial fibrillation and stroke risk - Re-Ly studies.
Kardiol Pol 2009;67(10):1151-2

Amara W, Ben Youssef I, Kamel J, Ghrissi I, Faron M, Khouadja A, Sergent J.
Hemorrhagic risk of different perioperative anticoagulation protocols in patients implanted with a cardiac pacemaker or defibrillator: Retrospective analysis in patients implanted in a community hospital.
Ann Cardiol Angeiol (Paris). 2009 Sep 20. [Epub ahead of print]

Blackmer AB, Oertel MD, Valgus JM.
Fondaparinux and the Management of Heparin-Induced Thrombocytopenia: The Journey Continues.
Ann Pharmacother. 2009 Sep 8. [Epub ahead of print]

Bonaca MP, Morrow DA.
SCH 530348: a novel oral thrombin receptor antagonist.
Future Cardiol. 2009;5(5):435-42

Bover R, Pérez-Gómez F, Maluenda MP, Asenjo S, Pérez-Saldaña R, Igea A, Suárez M, Coleto D, Fernández C.
Long-Term Follow-Up of Atrial Fibrillation Patients in the NASPEAF Study. Prospective Evaluation of Different Antiplatelet Treatments.
Rev Esp Cardiol 2009;62(9):992-1000

Camm AJ.
The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapY: dabigatran vs. warfarin.
Eur Heart J. 2009 Sep 21. [Epub ahead of print]

Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL, Hohnloser SH; for the ATHENA Investigators.
Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter.
Circulation. 2009 Sep 14. [Epub ahead of print]

Connolly SJ, Ezekowitz MD., Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, the RE-LY Steering Committee and Investigators
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
N Engl J Med 2009;361(12):1139-51

De Assis MC, Rabelo ER, Avila CW, Polanczyk CA, Rohde LE.
Improved oral anticoagulation after a dietary vitamin k-guided strategy: a randomized controlled trial.
Circulation. 2009;120(12):1115-22, 3 p following 1122. Epub 2009 Sep 8

Dentali F, Ageno W, Witt D, Malato A, Clark N, Garcia D, McCool K, Siragusa S, Dyke S, Crowther M; for the WARPED consortium.
Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists. A multi-centre, retrospective cohort study.
Thromb Haemost. 2009;102(3):501-504

Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD.
The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation.
Circulation. 2009;120(12):1029-35, 2 p following 1035. Epub 2009 Sep 8

Esmon CT.
Basic mechanisms and pathogenesis of venous thrombosis
Blood Rev 2009 Sep;23(5):225-9.

Fernlöf G, Sjöström BM, Lindell KM, Wall UE.
Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin.
Blood Coagul Fibrinolysis. 2009 Sep 7. [Epub ahead of print]

Fitzmaurice DA, Hobbs FD.
Anticoagulant management in patients with atrial fibrillation.
Semin Thromb Hemost. 2009;35(6):543-7. Epub 2009 Sep 28.

Freedman JE, Gersh BJ.
New therapies for stroke prevention in atrial fibrillation: the long road to enhanced efficacy.
Circulation. 2009;120(12):1024-6.

Galanaud JP, Sevestre-Pietri MA, Bosson JL, Laroche JP, Righini M, Brisot D, Boge G, van Kien AK, Gattolliat O, Bettarel-Binon C, Gris JC, Genty C, Quere I; The OPTIMEV-SFMV Investigators.
Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: Results from the OPTIMEV study.
Thromb Haemost. 2009;102(3):493-500

Gómez-Outes A, Suárez-Gea ML, Blázquez-Pérez A, Pozo-Hernández C, Vargas-Castrillón E.
Will oral rivaroxaban improve clinically relevant outcomes and thromboprophylaxis management in the orthopedic patient?
J Thromb Haemost 2009 Sep 18. [Epub ahead of print]

Harenberg J.
New anticoagulants in atrial fibrillation.
Semin Thromb Hemost. 2009;35(6):574-85. Epub 2009 Sep 28.

Hart RG, Halperin JL.
Do current guidelines result in overuse of warfarin anticoagulation in patients with atrial fibrillation?
Ann Intern Med 2009;151(5):355-6

Holmes M, Carroll C, Papaioannou D.
Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Health Technol Assess. 2009 Sep;13 Suppl 2:55-62.

Hylek EM.
Antithrombotic prophylaxis in elderly patients with atrial fibrillation.
Semin Thromb Hemost. 2009;35(6):548-53. Epub 2009 Sep 28.

Kahn SR.
How I manage the post thrombotic syndrome
Blood 2009 Sep 9. [Epub ahead of print]

Kakkar AK.
Prevention of Venous Thromboembolism in the Cancer Surgical Patient
J Clin Oncol. 2009 Sep 8. [Epub ahead of print]

Lee AY.
Anticoagulation in the Treatment of Established Venous Thromboembolism in Patients With Cancer.
J Clin Oncol. 2009 Sep 8. [Epub ahead of print]

Lepic K, Crowther MA
A logical approach to surgical thromboprophylaxis
Curr Opin Hematol 2009 Sep;16(5):397-401.

Levi M, de Peuter OR, Kamphuisen PW.
Management strategies for optimal control of anticoagulation in patients with atrial fibrillation.
Semin Thromb Hemost. 2009;35(6):560-7. Epub 2009 Sep 28.

Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T.
The impact of the fibrinolytic system on the risk of venous and arterial thrombosis.
Semin Thromb Hemost. 2009 Jul;35(5):468-77. Epub 2009 Sep 8

Millar JA.
Selection of medical patients for prophylaxis of venous thromboembolism based on analysis of the benefit-hazard ratio.
Intern Med J. 2009;39(9):606-12.

Mismetti P, Laporte S.
Dabigatran: clinical pharmacology.
Ann Fr Anesth Reanim. 2009 Sep;28(9 Suppl):S8-14.

Nair CK, Holmberg MJ, Aronow WS, Shen X, Li H, Lakkireddy D.
Thromboembolism in patients with atrial fibrillation with and without left atrial thrombus documented by transesophageal echocardiography.
Am J Ther. 2009 Sep-Oct;16(5):385-92.

No authors listed
Self-monitoring for patients on warfarin?
Drug Ther Bull. 2009;47(9):98-101

Piazza G, Fanikos J, Zayaruzny M, Goldhaber SZ.
Venous thromboembolic events in hospitalised medical patients.
Thromb Haemost. 2009;102(3):505-10

Piccini JP, Hernandez AF, Zhao X, Patel MR, Lewis WR, Peterson ED, Fonarow GC; Get With The Guidelines Steering Committee and Hospitals.
Quality of care for atrial fibrillation among patients hospitalized for heart failure.
J Am Coll Cardiol 2009;54(14)

Pisters R, de Vos CB, Nieuwlaat R, Crijns HJ.
Use and underuse of oral anticoagulation for stroke prevention in atrial fibrillation: old and new paradigms.
Semin Thromb Hemost. 2009;35(6):554-9. Epub 2009 Sep 28.

Rosencher N, Bellamy L.
Dabigatran (Pradaxa): efficacy and safety.
Ann Fr Anesth Reanim. 2009 Sep;28(9 Suppl):S15-22.

Sasaki S, Miyakoshi N, Matsuura H, Saitoh H, Kudoh D, Shimada Y.
Prospective randomized controlled trial on the effect of fondaparinux sodium for prevention of venous thromboembolism after hip fracture surgery.
J Orthop Sci. 2009;14(5):491-6. Epub 2009 Oct 3.

Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS.
The net clinical benefit of warfarin anticoagulation in atrial fibrillation.
The net clinical benefit of warfarin anticoagulation in atrial fibrillation. 2009;151(5):297-305

Spectre G, Varon D
New antiplatelet agents
Curr Opin Hematol 2009 Sep;16(5):365-70.

Streiff MB
Diagnosis and Initial Treatment of Venous Thromboembolism in Patients With Cancer.
J Clin Oncol. 2009 Sep 8. [Epub ahead of print]

Subramaniam V, Davis RC, Shantsila E, Lip GY.
Antithrombotic therapy for heart failure in sinus rhythm
Fundam Clin Pharmacol. 2009 Sep 4. [Epub ahead of print]

Vorob'eva NM, Panchenko EP, Kirienko AI, Dobrovol'skiĭ AB, Titaeva EV, Ermolina OV, Balakhonova TV, Andriiashkin VV, Leont'ev SG.
Warfarin or enoxaparin: the choice for the patient with venous thrombosis in the first month of treatment.
Ter Arkh. 2009;81(9):57-61.

Zinn A, Feit F.
Optimizing antithrombotic strategies in patients with concomitant indications for warfarin undergoing coronary artery stenting.
Am J Cardiol. 2009 Sep 7;104(5 Suppl):49C-54C

Chan KE, Lazarus JM, Thadhani R, Hakim RM.
Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation.
J Am Soc Nephrol 2009 Aug 27. [Epub ahead of print]

Chandrasekaran S, Ariaretnam SK, Tsung J, Dickison D.
Early mobilization after total knee replacement reduces the incidence of deep venous thrombosis
ANZ J Surg 2009;79(7-8):526-9.

Crandall MA, Horne BD, Day JD, Anderson JL, Muhlestein JB, Crandall BG, Weiss JP, Osborne JS, Lappé DL, Bunch TJ.
Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors
Pacing Clin Electrophysiol 2009 Aug;32(8):981-6.

Crowther MA, Warkentin TE.
Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents
J Thromb Haemost 2009;7 Suppl 1:107-10.

De Caterina R
The current role of anticoagulants in cardiovascular medicine
J Cardiovasc Med (Hagerstown) 2009 Aug;10(8):595-604

Dobesh PP.
Economic burden of venous thromboembolism in hospitalized patients
Pharmacotherapy 2009;29(8):943-53

Fitzmaurice D.
Atrial fibrillation and coagulation: Who and when?
Blood Rev. 2009 Aug 24. [Epub ahead of print]

Francis CW.
Prevention of Venous Thromboembolism in Hospitalized Patients With Cancer.
J Clin Oncol. 2009 Aug 24. [Epub ahead of print]

Gage BF.
Can we rely on RE-LY?
N Engl J Med. 2009;361(12):1200-2. Epub 2009 Aug 30

Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler PD.
The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study.
Circ Arrhythm Electrophysiol. 2009;2(5):474-80. Epub 2009 Aug 4.

Karami-Djurabi R, Klok FA, Kooiman J, Velthuis SI, Nijkeuter M, Huisman MV.
D-dimer Testing in Patients with Suspected Pulmonary Embolism and Impaired Renal Function
Am J Med 2009 Aug 19. [Epub ahead of print]

Kearon C.
Balancing risks and benefits of extended anticoagulant therapy for idiopathic venous thrombosis.
J Thromb Haemost 2009;7 Suppl 1:296-300.

Kessler CM.
The link between cancer and venous thromboembolism: a review
Am J Clin Oncol 2009;32(4 Suppl):S3-7.

Kössler J, Steigerwald U, Walter U.
Anticoagulants of primary haemostasis.
Hamostaseologie 2009;29(3):274-278

Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ
Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
N Engl J Med 2009;361:594-604.

Macfarlane AJ, Prasad GA, Chan VW, Brull R.
Does regional anaesthesia improve outcome after total hip arthroplasty? A systematic review.
Br J Anaesth 2009;103(3):335-45.

Neviaser AS, Chang C, Lyman S, Gonzales Della Valle A, Haas SB.
High Incidence of Complications From Enoxaparin Treatment After Arthroplasty
Clin Orthop Relat Res 2009 Aug 11. [Epub ahead of print]

Ordovás Baines JP.
Dabigatran and rivaroxaban, new oral anticoagulants for the treatment of venous thromboembolism.
Farm Hosp. 2009;33(3):123-4

Palareti G, Cosmi B.
Bleeding with anticoagulation therapy - Who is at risk, and how best to identify such patients.
Thromb Haemost 2009;102(2):268-78.

Quist-Paulsen P, Næss IA, Cannegieter SC, Romundstad PR, Christiansen SC, Rosendaal FR, Hammerstrøm J.
Arterial cardiovascular risk factors and venous thrombosis: results from a population based prospective study (the HUNT 2)
Haematologica. 2009 Aug 27. [Epub ahead of print]

Sanoski CA.
Clinical, Economic, and Quality of Life Impact of Atrial Fibrillation
J Manag Care Pharm 2009;15(6 Supp B):1-9.

Schulman S
Rivaroxaban in Orthopedic Surgery: A Change of Paradigm?
Clin Appl Thromb Hemost 2009 Aug 10. [Epub ahead of print]

Schulman S, Reilly PA.
Dabigatran Etexilate: Future Directions in Anticoagulant Treatment.
Clin Appl Thromb Hemost 2009 Aug 13. [Epub ahead of print]

Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ.
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
Pharmacogenomics 2009;10(8):1243-55.

Stangier J, Clemens A.
Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor
Clin Appl Thromb Hemost 2009 Aug 19. [Epub ahead of print]

Steffel J, Lüscher TF
Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors
J Cardiovasc Med (Hagerstown) 2009 Aug;10(8):616-23.

TRA*CER Executive and Steering Committees.
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
Am Heart J 2009;158(3):327-334.e4.

Verdú A, Maestre A, López P, Gil V, Martín-Hidalgo A, Castaño JA.
Clinical pathways as a healthcare tool: design, implementation and assessment of a clinical pathway for lower-extremity deep venous thrombosis
Qual Saf Health Care 2009;18(4):314-20.

Camporese G, Bernardi E
Low-molecular-weight heparin for thromboprophylaxis
Curr Opin Pulm Med 2009 Jul 9

Crandall MA, Bradley DJ, Packer DL, Asirvatham SJ
Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies
Mayo Clin Proc 2009 Jul;84(7):643-62

Johanson NA, Lachiewicz PF, Lieberman JR, Lotke PA, Parvizi J, Pellegrini V, Stringer TA, Tornetta P 3rd, Haralson RH 3rd, Watters WC 3rd
American academy of orthopaedic surgeons clinical practice guideline on. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty
J Bone Joint Surg Am 2009 Jul;91(7):1756-7

Prandoni P, Pesavento R, Sørensen HT, Gennaro N, Dalla Valle F, Minotto I, Perina F, Pengo V, Pagnan A.
Prevalence of heart diseases in patients with pulmonary embolism with and without peripheral venous thrombosis: findings from a cross-sectional survey.
Eur J Intern Med 2009;20(5):470-3. Epub 2009 Jul 4

Scarvelis D, Anderson J, Davis L, Forgie M, Lee J, Petersson L, Ramsay T, Wells PS.
Hospital mortality due to pulmonary embolism and an evaluation of the usefulness of preventative interventions
Thromb Res 2009 Jul 30. [Epub ahead of print]

Schulman S, Melinyshyn A, Ennis D, Rudd-Scott L.
Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range
Thromb Res 2009 Jul 28 [Epub ahead of print]

Spencer FA, Emery C, Joffe SW, Pacifico L, Lessard D, Reed G, Gore JM, Goldberg RJ
Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study
J Thromb Thrombolysis 2009 Jul 24. [Epub ahead of print]

Turpie AG
Direct Factor Xa and direct thrombin inhibitors: A clinical trial update
Curr Opin Drug Discov Devel 2009 Jul;12(4):497-508

Ageno W.
Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.
Expert Rev Cardiovasc Ther 2009;7:569-76

Amin A, Spyropoulos AC, Dobesh P, Shorr A, Hussein M, Mozaffari E, Benner JS
Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start)
Thromb Thrombolysis2009 Jun 23. [Epub ahead of print]

Borris LC
Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty
Arch Orthop Trauma Surg 2009 Jun 30. [Epub ahead of print]

Bump GM, Dandu M, Kaufman SR, Shojania KG, Flanders SA
How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta-analysis of randomized controlled trials
J Hosp Med 2009;4(5):289-97

Debourdeau P, Kassab Chahmi D, Le Gal G, Kriegel I, Desruennes E, Douard MC, Elalamy I, Meyer G, Mismetti P, Pavic M, Scrobohaci ML, Lévesque H, Renaudin JM, Farge D; on behalf of the working group of the SOR
2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group
Ann Oncol 2009 Jun 12 [Epub ahead of print]

Deinum J, Mattsson C, Inghardt T, Elg M
Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637
Thromb Haemost 2009;101:1051-9

Garcia D
Novel anticoagulants and the future of anticoagulation.
Thromb Res 2009;123 Suppl 4:S50-5

Halbfass P, Janko S, Dorwarth U, Riess G, Antoni D, Hoffmann E
Dilemma of antithrombotic therapy in anticoagulated atrial fibrillation patients squeezed between thrombosis and bleeding events: a single-centre experience.
Europace 2009 Jun 3 [Epub ahead of print]

Klok FA, Mos IC, Broek L, Tamsma JT, Rosendaal FR, de Roos A, Huisman MV
Risk of arterial cardiovascular events in patients after pulmonary embolism.
Blood 2009 Aug 20;114(8):1484-8. Epub 2009 Jun 23.

Kucher N, Puck M, Blaser J, Bucklar G, Eschmann E, Lüscher TF.
Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalized medical patients.
J Thromb Haemost 2009 Jun 9 [Epub ahead of print]

Masaki N, Suzuki M, Iwatsuka R, Mizukami A, Kumasaka L, Nagahori W, Ohno M, Matsumura A, Maruyama Y, Hashimoto Y
Effectiveness of Risk Stratification According to CHADS2 Score in Japanese Patients With Nonvalvular Atrial Fibrillation.
Int Heart J 2009;50(3):323-9

McAndrew CM, Fitzgerald SJ, Kraay MJ, Goldberg VM
Incidence of Postthrombotic Syndrome in Patients Undergoing Primary Total Knee Arthroplasty for Osteoarthritis.
Clin Orthop Relat Res 2009 Jun 19. [Epub ahead of print]

Mega J, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan E, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson C; on behalf of the ATLAS ACS-TIMI 46 study group.
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Lancet 2009 Jun 16. [Epub ahead of print]

Nadar SK, Goyal D, Shantsila E, Banerjee P, Lip GY
Fondaparinux: an overview.
Expert Rev Cardiovasc Ther 2009 Jun;7(6):577-85

Ng HJ, Lee LH
Trends in prevalence of deep venous thrombosis among hospitalised patients in an Asian institution.
Thromb Haemost 2009;10:1095-9

Nokes TJ, Keenan J.
Thromboprophylaxis in patients with lower limb immobilisation - review of current status.
Br J Haematol 2009 Jun 10 [Epub ahead of print]

Nutescu EA, Spinler SA, Wittkowsky A, Dager WE
Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
Ann Pharmacother 2009 Jun;43(6):1064-83

Park B, Messina L, Dargon P, Huang W, Ciocca R, Anderson FA
Recent Trends in Clinical Outcomes and Resource Utilization for Pulmonary Embolism in the United States: Findings From the Nationwide Inpatient Sample.
Chest 2009 Jun 12 [Epub ahead of print]

Pengo V, Cucchini U, Denas G, Erba N, Guazzaloca G, La Rosa L, De Micheli V, Testa S, Frontoni R, Prisco D, Nante G, Iliceto S; Italian Federation of Centers for the Diagnosis of Thrombosis and Management of Antithrombotic Therapies (FCSA)
Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study.
Circulation 2009 Jun 9;119(22):2920-7

Pineo GF, Hull RD
Economic and Practical Aspects of Thromboprophylaxis With Unfractionated and Low-Molecular-Weight Heparins in Hospitalized Medical Patients.
Clin Appl Thromb Hemost 2009 Jun 10. [Epub ahead of print]

Prineas RJ, Soliman EZ, Howard G, Howard VJ, Cushman M, Zhang ZM, Moy CS
The sensitivity of the method used to detect atrial fibrillation in population studies affects group-specific prevalence estimates: ethnic and regional distribution of atrial fibrillation in the REGARDS study
J Epidemiol 2009;19(4):177-81. Epub 2009 Jun 27

Shantsila E, Lip GY, Chong BH
Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management.
Chest 2009 Jun; 135(6):1651-64

Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM
Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation.
Am Heart J 2009;157:1064-73

Volkmann H, Walter M, Bergmann C, Rose E, Krpciar V, Vetter S
Antithrombotic therapy in atrial fibrillation : When vitamin K antagonists? When aspirin? When heparine? When combinations of anticoagulant and antiplatelet drugs?
Herzschrittmacherther Elektrophysiol 2009 Jun 20 [Epub ahead of print] German

Wakefield TW, McLafferty RB, Lohr JM, Caprini JA, Gillespie DL, Passman MA; Executive Committee of the American Venous Forum
Call to action to prevent venous thromboembolism.
J Vasc Surg 2009 Jun;49(6):1620-3

Wells PS, Le Gal G, Tierney S, Carrier M
Practical application of the 10-mg warfarin initiation nomogram.
Blood Coagul Fibrinolysis 2009 Jun 10. [Epub ahead of print]

APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
Circulation 2009;119:2877-85.

Camporese G, Bernardi E, Noventa F.
Prevention of deep venous thrombosis after knee arthroscopy: Recent advances.
Recenti Prog Med. 2009;100(5):227-32.

Cook D, Tkaczyk A, Lutz K, McMullin J, Haynes RB, Douketis J
Thromboprophylaxis for hospitalized medical patients: a multicenter qualitative study.
J Hosp Med 2009 May;4(5):269-75.

Cusick LA, Beverland DE
The incidence of fatal pulmonary embolism after primary hip and knee replacement in a consecutive series of 4253 patients
J Bone Joint Surg Br 2009 May;91(5):645-8

Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement
J Bone Joint Surg Br 2009 May;91(5):636-44

Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
Am Heart J 2009 May;157(5):805-10, 810.e1-2

Persson LM, Lapidus LJ, Lärfars G, Rosfors S
Asymptomatic Deep Venous Thrombosis is Associated with a Low Risk of Post-thrombotic Syndrome.
Eur J Vasc Endovasc Surg 2009 May 29 [Epub ahead of print]

Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D
Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment.
Thromb Haemost. 2009 May;101(5):938-42

Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D.
Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years.
J Am Coll Cardiol. 2009;54(11):999-1002

Prandoni P, Prins MH, Lensing AW, Ghirarduzzi A, Ageno W, Imberti D, Scannapieco G, Ambrosio GB, Pesavento R, Cuppini S, Quintavalla R, Agnelli G; AESOPUS Investigators
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial.
Ann Intern Med 2009 May 5;150(9):577-85

Squizzato A, Micieli E, Galli M, Gibson N, Gerdes VE, Dentali F, Buller H, Ageno W, Venco A
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice.
Thromb Res 2009 May 19 [Epub ahead of print]

Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; for the RECORD4 Investigators.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
Lancet 2009 May 1 [Epub ahead of print]

Baker WL, Cios DA, Sander SD, Coleman CI
Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States.
J Manag Care Pharm 2009 Apr;15(3):244-52

Borris LC
Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty
Expert Opin Pharmacother2009 Apr;10(6):1083-8

Chin PL, Amin MS, Yang KY, Yeo SJ, Lo NN
Thromboembolic prophylaxis for total knee arthroplasty in Asian patients: a randomised controlled trial
J Orthop Surg (Hong Kong) 2009 Apr;17(1):1-5

De Caterina R, Kristensen SD, Renda G
New anticoagulants for atrial fibrillation
J Cardiovasc Med (Hagerstown)2009 Apr 10

Enden T, Kløw NE, Sandvik L, Slagsvold CE, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbæk G, Sandset PM; For the Cavent Study Group
Catheter-directed thrombolysis versus anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short term patency
J Thromb Haemost 2009 Apr 30. [Epub ahead of print]

Hildemann SK, Bode C.
Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1.
Hamostaseologie. 2009;29:349–55.

Jiang X, Crain EJ, Luettgen JM, Schumacher WA, Wong PC
Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro
Thromb Haemost 2009 Apr;101(4):780-2

Lassen MR, Dahl OE, Mismetti P, Destrée D, Turpie AG
AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery--TREK: a dose-ranging study.
J Thromb Haemost 2009 Apr;7(4):566-72. Epub 2009 Jan 24

Merli GJ
Deep-vein thrombosis in malignancy: How long should patients be treated, and with what?
Catheter Cardiovasc Interv 2009 Apr 13;74(S1):S27-S34. [Epub ahead of print]

Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A, Lewalter T, Ravens U, Meinertz T, Breithardt G, Steinbeck G.
The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management.
Europace. 2009 Apr; 11(4):423-34 [Epub 2009 Jan 18]

Nicolau JC, Cohen M, Montalescot G
Differences Among Low-Molecular Weight Heparins: Evidence in Patients With Acute Coronary Syndromes.
J Cardiovasc Pharmacol 2009 Apr 10. [Epub ahead of print]

van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, Koudstaal PJ, Petersen P, Perez-Gomez F, Knottnerus JA, Boode B, Ezekowitz MD, Singer DE.
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators.
Stroke 2009 Apr;40(4):1410-6. Epub 2009 Jan 29

Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA; TRA-PCI Investigators
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
Lancet 2009 Mar 14;373(9667):919-28

Cohen AT, Maillardet L, Yavin Y
Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?
Thromb Haemost 2009 Mar;101(3):422-7

Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, Singer DE; ATRIA Study Investigators
Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.
Circulation 2009 Mar 17;119(10):1363-9. Epub 2009 Mar 2

Johanson NA, Lachiewicz PF, Lieberman JR, Lotke PA, Parvizi J, Pellegrini V, Stringer TA, Tornetta P 3rd, Haralson RH 3rd, Watters WC 3rd
Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty.
J Am Acad Orthop Surg 2009 Mar;17(3):183-96

Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG, Roberts C, van den Besselaar AM, van der Meer FJ, Tripodi A, Palareti G, Shiach C, Bryan S, Samama M, Burgess-Wilson M, Heagerty A, Maccallum P, Wright D, Jespersen J; European Action on Anticoagulation (EAA)
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program.
Thromb Haemost 2009 Mar;101(3):487-94

Rietbrock S, Plumb JM, Gallagher AM, van Staa TP
How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database.
Thromb Haemost 2009 Mar;101(3):527-34

Rochat MC, Waeber G, Wasserfallen JB, Nakov K, Aujesky D
Hospitalized women experiencing an episode of excessive oral anticoagulation had a higher bleeding risk than men.
J Womens Health (Larchmt) 2009 Mar; 18(3):321-6

Spence D
Mechanisms of thrombogenesis in atrial fibrillation.
Lancet. 2009 Mar 21; 373(9668):1006

Stashenko GJ, Hargett CW, Tapson VFm
Thrombolytic therapy for venous thromboembolism: Current clinical practice.
J Hosp Med. 2009 Mar 5. [Epub ahead of print]

White RH, Keenan CR
Effects of race and ethnicity on the incidence of venous thromboembolism.
Thromb Res. 2009;123 Suppl 4:S11-7

Bounameaux H
The novel anticoagulants: entering a new era
Swiss Med Wkly 2009 Feb 7;139(5-6):60-4

Chapman NH, Brighton T, Harris MF, Caplan GA, Braithwaite J, Chong BH
Venous thromboembolism - management in general practice
Aust Fam Physician 2009 Jan-Feb;38(1-2):36-40

Dranitsaris G, Stumpo C, Smith R, Bartle W
Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery
Am J Cardiovasc Drugs 2009;9(1):45-58. doi: 10.2165/00129784-200909010-00005

Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J
American association of orthopedic surgeons and american college of chest physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients?
Chest. 2009 Feb;135(2):513-20

Haas S
New anticoagulants - towards the development of an "ideal" anticoagulant.
Vasa 2009 Feb;38(1):13-29

Harenberg J
Development of new anticoagulants: present and future.
Semin Thromb Hemost 2008 Nov;34(8):779-93. Epub 2009 Feb 12

Lang D, Weinz C, Schwarz T, Kubitza D, Mueck W
Metabolism and excretion of rivaroxaban - an oral, direct Factor Xa inhibitor - in rats, dogs and humans
Drug Metab Dispos 2009 Feb 5 [Epub ahead of print]

Prandoni P, Kahn SR
Post-thrombotic syndrome: prevalence, prognostication and need for progress.
Br J Haematol 2009 Feb 12. [Epub ahead of print]

Tripodi A, van den Besselaar A
Laboratory monitoring of anticoagulation: where do we stand?
Semin Thromb Hemost. 2009 Feb;35(1):34-41. Epub 2009 Mar 23.

Abrams PJ, Emerson CR.
Rivaroxaban: a novel, oral, direct factor xa inhibitor.
Pharmacotherapy. 2009;29:167-81

Beam DM, Courtney DM, Kabrhel C, Moore CL, Richman PB, Kline JA
Risk of Thromboembolism Varies, Depending on Category of Immobility in Outpatients
Ann Emerg Med. 2009 Jan 7. [Epub ahead of print]

Bryniarski L, Pelc-Nowicka A, Zabojszcz M, Mirek-Bryniarska E
Dual antiplatelet therapy and antithrombotic treatment: Recommendations and controversies
Cardiol J 2009;16(2):179-189

Eikelboom JE, Weitz JI
Dabigatran etexilate for prevention of venous thromboembolism
Thromb Haemost 2009 101:2-4

Eriksson BI, Quinlan DJ, Weitz JI
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development
Clin Pharmacokinet 2009;48(1):1-22. doi: 10.2165/0003088-200948010-00001

Farley TM, Lewis D, Macaulay TE
In the pipeline: new oral anticoagulants for the prevention of venous thromboembolism.
Orthopedics 2009 Jan;32(1) pii: orthosupersite.com/view.asp?rID=35867.

Haas S
Rivaroxaban - an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.
Eur J Haematol 2009 Jan 29 [Epub ahead of print]

Karthikeyan G, Eikelboom JW, Hirsh J
New oral anticoagulants: not quite there yet.
Pol Arch Med Wewn 2009 Jan-Feb;119(1-2):53-8

Labarère J, Sevestre MA, Belmin J, Legagneux A, Barrellier MT, Thiel H, Roux PL, Pernod G, Bosson JL; for the Association pour la Promotion de l'Angiologie Hospitalière (APAH)
Low-Molecular-Weight Heparin Prophylaxis of Deep Vein Thrombosis for Older Patients with Restricted Mobility: Propensity Analyses of Data from Two Multicentre, Cross-Sectional Studies.
Drugs Aging 2009;26(3):263-271

Lassen MR, Dahl OE, Mismetti P, Destrée D, Turpie AG
AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery - TREK: a dose-ranging study.
J Thromb Haemost 2009 Jan 24 [Epub ahead of print]

Monkman K, Lazo-Langner A, Kovacs MJ
A 10 mg warfarin initiation nomogram is safe and effective in outpatients starting oral anticoagulant therapy for venous thromboembolism.
Thromb Res. 2009 Jan 18. [Epub ahead of print]

Mosca L, Grady D, Barrett-Connor E, et al.
Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease.
Stroke 2009 Jan;40(1):147-55. Epub 2008 Oct 23.

Pomp ER, Doggen CJ, Vos HL, Reitsma PH, Rosendaal FR
Polymorphisms in the protein C gene as risk factor for venous thrombosis.
Thromb Haemost 2009;101:62-7.

Rasmussen MS, Jorgensen LN, Wille-Jorgensen P
Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
Cochrane Database Syst Rev 2009 Jan 21(1):CD004318.

Siragusa S, Caramazza D, Malato A
How should we determine length of anticoagulation after proximal deep vein thrombosis of the lower limbs?
Br J Haematol. 2009 Jan 16. [Epub ahead of print]

Spiess JL
Can I stop the warfarin? A review of the risks and benefits of discontinuing anticoagulation
J Palliat Med 2009 Jan; 12(1):83-7

Taliani MR, et al.
Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities.
Thromb Haemost. 2009; 101(3):596-598

Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
Clin Ther. 2009 Jan; 31(1):194-212

van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, Koudstaal PJ, Petersen P, Perez-Gomez F, Knottnerus JA, Boode B, Ezekowitz MD, Singer DE.
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators.
Stroke. 2009;40(4):1410-6. Epub 2009 Jan 29.

Akl EA, Terrenato I, Barba M, Sperati F, Muti P, Schünemann HJ.
Extended perioperative thromboprophylaxis in patients with cancer. A systematic review.
Thromb Haemost. 2008;100:1

Arora RR, Rai F
Antiplatelet Intervention in Acute Coronary Syndrome.
Am J Ther. 2008 Dec 15. [Epub ahead of print]

Baroletti S, Piovella C, Fanikos J, Labreche M, Lin J, Goldhaber SZ
Heparin-induced thrombocytopenia (HIT): Clinical and economic outcomes
Thromb Haemost 2008;100:1130-5

Borris LC
New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban
Vasc Health Risk Manag. 2008;4(4):855-62.

Bounameaux H, Perrier A
Duration of anticoagulation therapy for venous thromboembolism
Hematology Am Soc Hematol Educ Program 2008;2008:252-8

Chintala M, Shimizu K, Ogawa M, Yamaguchi H, Doi M, Jensen P
Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease
J Pharmacol Sci 2008;108(4):433-8

Francis CW
New issues in oral anticoagulants
Hematology Am Soc Hematol Educ Program 2008;2008:259-65

Hill CE, Duncan A
Overview of pharmacogenetics in anticoagulation therapy.
Clin Lab Med 2008 Dec;28(4):513-24

Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM
Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control.
Thromb Res. 2008 Dec 3. [Epub ahead of print]

Pesce V, Patella V, Scaraggi A, Petrera M, Sammarco G
Thrombocytopenia after total knee arthroplasty.
Orthopedics 2008 Dec;31(12). pii: orthosupersite.com/view.asp?rID=32934.

Righini M, Le Gal G, Aujesky D, Roy PM, Sanchez O, Verschuren F, Kossovsky M, Bressollette L, Meyer G, Perrier A, Bounameaux H
Complete venous ultrasound in outpatients with suspected pulmonary embolism.
J Thromb Haemost 2008 Dec 20 [Epub ahead of print]

Tay KH, Lane DA, Lip GY
Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: is clopidogrel any safer than aspirin when combined with warfarin?
Thromb Haemost 2008; 100:955-7

Conget F, Otero R, Jiménez D, Martí D, Escobar C, Rodríguez C, Uresandi F, Cabezudo MA, Nauffal D, Oribe M, Yusen R
Short-term clinical outcome after acute symptomatic pulmonary embolism
Thromb Haemost 2008 Nov;100(5):937-42

Deitelzweig SB, Becker R, Lin J, Benner J.
Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism
Thromb Haemost 2008 Nov;100(5):810-20

Franchini M, Mannucci PM
Venous and arterial thrombosis: different sides of the same coin?
Eur J Intern Med 2008 Nov;19(7):476-81. Epub 2008 Mar 20

Glurich I, Burmester JK, Caldwell MD
Understanding the pharmacogenetic approach to warfarin dosing
Heart Fail Rev 2008 Nov 8. [Epub ahead of print]

Heck CA, Brown CR, Richardson WJ
Venous thromboembolism in spine surgery.
J Am Acad Orthop Surg 2008 Nov;16(11):656-64

Hunt BJ
The prevention of hospital-acquired venous thromboembolism in the United Kingdom
Br J Haematol 2008 Nov 29 [Epub ahead of print]

Janjua M, Badshah A, Matta F, Danescu LG, Yaekoub AY, Stein PD
Treatment of acute pulmonary embolism as outpatients or following early discharge. A systematic review.
Thromb Haemost 2008 Nov;100(5):756-61

Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Lamping DL, Johri M, Ginsberg JS
Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis.
Ann Intern Med 2008 Nov 18;149(10):698-707

Levy JH, Tanaka KA, Dietrich W
Perioperative hemostatic management of patients treated with vitamin K antagonists
Anesthesiology 2008 Nov;109(5):918-26

Milbrink J, Bergqvist D
The incidence of symptomatic venous thromboembolic events in orthopaedic surgery when using routine thromboprophylaxis.
Vasa. 2008 Nov;37(4):353-7

Millar JA
Rational thromboprophylaxis in medical inpatients: not quite there yet.
Med J Aust 2008 Nov 3;189(9):504-6.

Nieto JA, Camara T, Gonzalez-Higueras E, Ruiz-Gimenez N, Guijarro R, Marchena PJ, Monreal M; for the RIETE Investigators.
Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry.
Thromb Haemost 2008;100(5):789-796.

Roldán V, Marín F
Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
Thromb Haemost. 2008 Nov;100(5):754-5.

Rubboli A, Halperin JL
Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
Thromb Haemost. 2008 Nov; 100(5):752-3

Selby R, Geerts W, Ofosu FA, Craven S, Dewar L, Phillips A, Szalai JP
Hypercoagulability after trauma: Hemostatic changes and relationship to venous thromboembolism.
Thromb Res 2008 Nov 26 [Epub ahead of print]

Thachil J, Gatt A, Martlew V.
Management of surgical patients receiving anticoagulation and antiplatelet agents.
Br J Surg 2008 Nov 7; 95(12):1437-1448 [Epub ahead of print]

Alonso-Coello P, Montori VM, Sola I, Schunemann HJ, Devereaux P, Charles C, Roura M, Diaz MG, Souto JC, Alonso R, Oliver S, Ruiz R, Coll-Vinent B, Diez AI, Gich I, Guyatt G.
Values and preferences in oral anticoagulation in patients with atrial fibrilation: physicians' and patients' perspectives. Protocol for a two-phase study.
BMC Health Serv Res. 2008 Oct 27;8(1):221. [Epub ahead of print]

Cohen M, Hoekstra J
The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention
Am J Emerg Med 2008 Oct;26(8):932-41.

Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S; on behalf of the ACTIVE W Investigators
Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
Circulation 2008 Oct 27 [Epub ahead of print]

Eischer L, Gartner V, Schulman S, Kyrle PA, Eichinger S; for the AUREC-FVIII investigators (as listed in acknowledgements)
6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII
Ann Hematol 2008 Oct 18. [Epub ahead of print]

Furusho H, Takamura M, Takata S, Sakagami S, Hirazawa M, Kato T, Murai H, Okajima M, Kaneko S
Current Status of Anticoagulation Therapy for Elderly Atrial Fibrillation Patients in Japan
Circ J 2008 Oct 14. [Epub ahead of print]

Janin S, Meneveau N, Mahemuti A, Descotes-Genon V, Dutheil J, Chopard R, Seronde MF, Schiele F, Bernard Y, Bassand JP
Safety and efficacy of fondaparinux as an adjunctive treatment to thrombolysis in patients with high and intermediate risk pulmonary embolism.
J Thromb Thrombolysis 2008 Oct 25 [Epub ahead of print]

Jolobe OM
Intensity of anticoagulation in octogenarians with nonvalvular atrial fibrillation
J Am Geriatr Soc 2008 Oct;56(10):1967-8

Komotar RJ, Starke RM, Connolly ES Jr
Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
Neurosurgery 2008 Oct;63(4):N10-1

Laporte S, Mismetti P, Decousus H; RIETE Investigators
Clinical Predictors for Fatal Pulmonary Embolism in 15,520 Patients with Venous Thromboembolism: Findings from the Registro Informatizado de la Enfermedad Thrombo Embolica Venosa (RIETE) Registry.
J Vasc Surg 2008 Oct;48(4):1063

Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
Pharmacogenomics 2008 Oct;9(10):1445-58.

Nieuwlaat R, Connolly S
Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes.
Heart 2008 Oct 24 [Epub ahead of print]

Osborne NH, Wakefield TW, Henke PK
Venous Thromboembolism in Cancer Patients Undergoing Major Surgery.
Ann Surg Oncol 2008 Oct 8 [Epub ahead of print]

Parvizi J, Azzam K, Rothman RH
Deep venous thrombosis prophylaxis for total joint arthroplasty: American Academy of Orthopaedic Surgeons guidelines.
J Arthroplasty 2008 Oct;23(7 Suppl):2-5

Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D
Apixaban metabolism and pharmacokinetics following oral administration to humans.
Drug Metab Dispos 2008 Oct 2 [Epub ahead of print]

Ramos J, Perrotta C, Badariotti G, Berenstein G
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
Cochrane Database Syst Rev 2008 Oct 8;(4):CD005259

Rose AJ, Ozonoff A, Henault LE, Hylek EM
Warfarin for atrial fibrillation in community-based practise.
J Thromb Haemost. 2008 Oct; 6(10):1647-54

Sandercock PA, Counsell C, Kamal AK
Anticoagulants for acute ischaemic stroke.
Cochrane Database Syst Rev 2008 Oct 8; (4):CD000024

Testroote M, Stigter W, de Visser DC, Janzing H
Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization.
Cochrane Database Syst Rev 2008 Oct 8;(4):CD006681.

Tick LW, Kramer MH, Rosendaal FR, Faber WR, Doggen CJ.
Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis.
J Thromb Haemost 2008 Oct 4 [Epub ahead of print]

Walker AM, Bennett D
Epidemiology and outcomes in patients with atrial fibrillation in the United States.
Heart Rhythm. 2008 Oct; 5(10):1365-72 Epub 2008 Jul 17.

Bauer KA
New anticoagulants
Curr Opin Hematol 2008 Sep;15(5):509-15

Callaghan JJ, Warth LC, Hoballah JJ, Liu SS, Wells CW
Evaluation of deep venous thrombosis prophylaxis in low-risk patients undergoing total knee arthroplasty
J Arthroplasty 2008 Sep;23(6 Suppl 1):20-4

Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y, Albert M, Granton J, Hébert P, Pagliarello G, Marshall J, Fowler R, Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D, Crowther M; Canadian Critical Care Trials Group
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study
Arch Intern Med 2008 Sep 8;168(16):1805-12

Douketis JD
Prevention of venous thromboembolism in hospitalized medical patients: addressing some practical questions
Curr Opin Pulm Med 2008 Sep;14(5):381-8

Fuji T, Ochi T, Niwa S, Fujita S
Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin
J Orthop Sci 2008 Sep;13(5):442-51. Epub 2008 Oct 9

Hu D, Sun Y
Epidemiology, risk factors for stroke, and management of atrial fibrillation in China.
Am Coll Cardiol 2008 Sep 2;52(10):865-8

Kwong LM, Happe LE, Horblyuk R, Farrelly E
Decreased venous thromboembolism with injectable vs oral anticoagulation after discharge for major orthopedic surgery.
J Arthroplasty 2008 Sep;23(6 Suppl 1):25-30.

Lee A
VTE in Patients with Cancer-Diagnosis, Prevention, and Treatment.
Thromb Res 2008 Sep 26 [Epub ahead of print]

Lopes RD, Piccini JP, Hylek EM, Granger CB, Alexander JH
Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician.
J Thromb Thrombolysis 2008 Sep 21. [Epub ahead of print]

Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kälebo P, Muelhofer E, Misselwitz F, Eriksson BI
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Thromb Haemost 2008 Sep; 100(3):453-61

Righini M, Bounameaux H
Clinical relevance of distal deep vein thrombosis.
Curr Opin Pulm Med 2008 Sep;14(5):408-13

Schelleman H, Limdi NA, Kimmel SE
Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics.
Pharmacogenomics 2008 Sep; 9(9):1331-46

Schellong SM
Venous ultrasonography in symptomatic and asymptomatic patients: an updated review.
Curr Opin Pulm Med 2008 Sep; 14(5):374-80

Seitz CS, Brocker EB, Trautmann A
Management of allergy to heparins in postoperative care: subcutaneous allergy and intravenous tolerance.
Dermatol Online J 2008 Sep 15;14(9):4

Seto AC, Kenyon K, Wittkowsky AK
Discrepancies in identification of major bleeding events in patients taking warfarin.
Pharmacotherapy 2008 Sep; 28(9):1098-103

Shen AY, Chen W, Yao JF, Brar SS, Wang X, Go AS
Effect of race/ethnicity on the efficacy of warfarin : potential implications for prevention of stroke in patients with atrial fibrillation.
CNS Drugs 2008; 22(10):815-25

Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K
Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment.
J Clin Pharmacol. 2008 Sep 30 [Epub ahead of print]

Tanne JH
Most patients at risk of stroke fail to get adequate anticoagulation.
BMJ 2008 Sep 4; 337:a1529. doi: 10.1136/bmj.a1529.

Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Zamorano JL, Andreotti F, Ascherman M, Athanassopoulos G, De Sutter J, Fitzmaurice D, Forster T, Heras M, Jondeau G, Kjeldsen K, Knuuti J, Lang I, Lenzen M, Lopez-Sendon J, Nihoyannopoulos P, Perez Isla L, Schwehr U, Torraca L, Vachiery JL; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology
Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).
Eur Heart J 2008 Sep;29(18):2276-315. Epub 2008 Aug 30.

Trujillo-Santos J, Nieto JA, Tiberio G, Piccioli A, Di Micco P, Prandoni P, Monreal M; RIETE Registry
Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry.
Thromb Haemost 2008 Sep;100(3):435-9

Wiedermann CJ, Stockner I
Warfarin-induced bleeding complications - clinical presentation and therapeutic options.
Thromb Res 2008; 122 Suppl 2:S13-8

Zhou Z, Hu D
An Epidemiological Study on the Prevalence of Atrial Fibrillation in the Chinese Population of Mainland China.
J Epidemiol 2008 Sep 8 [Epub ahead of print]

Acosta S, Alhadad A, Svensson P, Ekberg O.
Epidemiology, risk and prognostic factors in mesenteric venous thrombosis.
Br J Surg 2008 Aug 21. [Epub ahead of print]

Ageno W, Dentali F.
Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se.
Thromb Haemost 2008 Aug;100(2):181-3.

Aissaoui N, Martins E, Mouly S, Weber S, Meune C.
A meta-analysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both.
Int J Cardiol 2008 Aug 6. [Epub ahead of print]

Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T
High Rate of Unprovoked Recurrent Venous Thrombosis is Associated with a High Thrombin Generating Potential in a Prospective Cohort Study
J Thromb Haemost 2008 Aug 1. [Epub ahead of print]

Borris LC, Breindahl M, Lassen MR, Pap AF, Misselwitz F
Differences in Urinary Prothrombin Fragment 1+2 Levels After Total Hip Replacement in Relation to Venous Thromboembolism and Bleeding Events
J Thromb Haemost 2008 Aug 1. [Epub ahead of print]

Bungard TJ, Koshman SL, Tsuyuki RT
Patient preferences for ongoing warfarin management after receiving care by an anticoagulation management service
Am J Health Syst Pharm 2008 Aug 15;65(16):1498-500

Clark NP, Witt DM, Delate T, Trapp M, Garcia D, Ageno W, Hylek EM, Crowther MA
Thromboembolic Consequences of Subtherapeutic Anticoagulation in Patients Stabilized on Warfarin Therapy: The Low INR Study
Pharmacotherapy 2008 Aug;28(8):960-7

Gallus A
Which patients with venous thromboembolism are at risk for fatal pulmonary embolism?
Nat Clin Pract Cardiovasc Med 2008 Aug 5. [Epub ahead of print]

Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK
Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated.
Stroke 2008 Aug 28 [Epub ahead of print]

Gulseth MP, Michaud J, Nutescu EA
Rivaroxaban: an oral direct inhibitor of factor Xa.
Am J Health Syst Pharm 2008 Aug 15;65(16):1520-9

Ho WK, Hankey GJ, Eikelboom JW
The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia.
Med J Aust 2008 Aug 4;189(3):144-7

Hylek EM, Frison L, Henault LE, Cupples A
Disparate Stroke Rates on Warfarin Among Contemporaneous Cohorts With Atrial Fibrillation. Potential Insights Into Risk From a Comparative Analysis of SPORTIF III Versus SPORTIF V.
Stroke 2008 Aug 14

Levi M
Self-management of anticoagulation
Expert Rev Cardiovasc Ther 2008 Aug; 6(7):979-85

Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schunemann HJ.
Low-Molecular-Weight Heparins are superior to Vitamin K Antagonists for the long term treatment of venous thromboembolism in patients with cancer: a Cochrane systematic review.
J Exp Clin Cancer Res 2008 Jul 18;27(1):21. [Epub ahead of print]

Audebert HJ, Schenk B, Tietz V, Schenkel J, Heuschmann PU
Initiation of Oral Anticoagulation after Acute Ischaemic Stroke or Transient Ischaemic Attack: Timing and Complications of Overlapping Heparin or Conventional Treatment
Cerebrovasc Dis 2008 Jul 15;26(2):171-177. [Epub ahead of print]

Barnes GD, Froehlich JB
Anticoagulation: where we are and where we need to go
J Thromb Thrombolysis 2008 Jul 18. [Epub ahead of print]

Beri A, Punnam SR
Anticoagulation in Patients with Acute Ischemic Stroke and Atrial Fibrillation-a Balance of Risks and Benefits
Ther 2008 Jul 21. [Epub ahead of print]

Brækkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB
Family history of myocardial infarction is an independent risk factor for venous thromboembolism - the Tromsø study
J Thromb Haemost 2008 Jul 26 [Epub ahead of print]

Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study
Blood 2008 Jul 11 [Epub ahead of print]

Camporese G, Bernardi E, Prandoni P, Noventa F, Verlato F, Simioni P, Ntita K, Salmistraro G, Frangos C, Rossi F, Cordova R, Franz F, Zucchetta P, Kontothanassis D, Andreozzi GM; KANT (Knee Arthroscopy Nadroparin Thromboprophylaxis) Study Group
Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial
Ann Intern Med 2008 Jul 15;149(2):73-82

Collen JF, Jackson JL, Shorr AF, Moores LK
Prevention of venous thromboembolism in neurosurgery: a meta-analysis
Chest 2008 Jul 18. [Epub ahead of print]

Douen AG, Sabih M, Pageau N
Thrombus detection by echocardiography in patients with acute ischemic stroke and chronic or new-onset atrial fibrillation
J Stroke Cerebrovasc Dis 2008 Jul-Aug;17(4):208-11

Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U, Nashef SA; on behalf of the EACTS Audit and Guidelines Committee
Guideline on antiplatelet and anticoagulation management in cardiac surgery
Eur J Cardiothorac Surg 2008 Jul;34(1):73-92. Epub 2008 Mar 28.

Fulco PP, Zingone MM, Higginson RT
Possible antiretroviral therapy-warfarin drug interaction
Pharmacotherapy 2008 Jul;28(7):945-9

Hallevi H, Albright KC, Martin-Schild S, Barreto AD, Savitz SI, Escobar MA, Gonzales NR, Noser EA, Illoh K, Grotta JC
Anticoagulation After Cardioembolic Stroke: To Bridge or Not to Bridge?
Arch Neurol 2008 Jul 14. [Epub ahead of print]

Kakkar AK, Brenner B, Dahl OE, et al., for the RECORD2 investigators.
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled study.
The Lancet 2008; 372:31-39

Khoobiar S, Mejevoi N, Kaid K, Boiangiu C, Setty S, Tanwir A, Khalid K, Cohen M
Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen.
J Thromb Thrombolysis 2008 Jul 18 [Epub ahead of print]

Manzano-Fernández S, Pastor FJ, Marín F, Cambronero F, Caro C, Pascual-Figal DA, Garrido IP, Pinar E, Valdés M, Lip GY
Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing.
Chest 2008 Jul 18. [Epub ahead of print]

Paauw JD, Borders H, Ingalls N, Boomstra S, Lambke S, Fedeson B, Goldsmith A, Davis AT
The Incidence of PICC Line-Associated Thrombosis With and Without the Use of Prophylactic Anticoagulants.
JPEN J Parenter Enteral Nutr 2008 July-August;32(4):443-447.

Sandercock PA, Counsell C, Tseng MC
Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke.
Cochrane Database Syst Rev 2008 Jul 16;(3):CD000119.

Savi P, Herault JP, Duchaussoy P, Millet L, Schaeffer P, Petitou M, Bono F, Herbert JM
Reversible biotinylated oligosaccharides. A new approach for a better management of anticoagulant therapy.
J Thromb Haemost 2008 Jul 19 [Epub ahead of print]

Verheugt FW
Long-term anticoagulation in patients with coronary disease, and future developments.
Curr Opin Cardiol 2008 Jul;23(4):315-9

Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, Kornek G, Marosi C, Wagner O, Zielinski C, Pabinger I
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients - results from the Vienna Cancer and Thrombosis Study (CATS)
Blood. 2008 Jun 6. [Epub ahead of print]

Barantke M, Bonnemeier H
Factor Xa inactivation in acute coronary syndrome
Curr Pharm Des 2008;14(12):1186-90.

Bottaro FJ, Elizondo MC, Doti C, Bruetman JE, Perez Moreno PD, Bullorsky EO, Ceresetto JM
Efficacy of extended thrombo-prophylaxis in major abdominal surgery: What does the evidence show? A meta-analysis
Thromb Haemost 2008 Jun;99(6):1104-11

Eriksson BI, Borris LC, Friedman RJ, et al.
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
N Engl J Med 2008; 358:2765-2775

Franchini M, Mannucci PM
Interactions between genotype and phenotype in bleeding and thrombosis
Haematologica 2008; 93(5):649-52

Gandolfo C, Balestrino M, Burrone A, Del Sette M, Finocchi C
Stroke due to atrial fibrillation and the attitude to prescribing anticoagulant prevention in Italy. : A prospective study of a consecutive stroke population admitted to a comprehensive stroke unit.
J Neurol 2008 Jun 20 [Epub ahead of print]

Garcia DA, Witt DM, Hylek E, Wittkowsky AK, Nutescu EA, Jacobson A, Moll S, Merli GJ, Crowther M, Earl L, Becker RC, Oertel L, Jaffer A, Ansell JE
Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation Forum (July/August).
Ann Pharmacother 2008 Jun 17[Epub ahead of print]

Kakkar AK
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer.
Clin Adv Hematol Oncol 2008 Jun;6(6):416-417

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
N Engl J Med 2008; 358(26):2776-86

On behalf of the Botticelli investigators, the writing committee, Buller H, Deitchman D, Prins M, Segers A
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep-vein thrombosis. The Botticelli DVT dose-ranging study.
J Thromb Haemost 2008 Jun 6 [Epub ahead of print]

Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM
Rivaroxaban, an oral direct factor Xa inhibitor.
Expert Opin Investig Drugs 2008 Jun;17(6):925-937

Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG, Roberts C, van den Besselaar AM, van der Meer FJ, Tripodi A, Palareti G, Shiach C, Bryan S, Samama M, Burgess-Wilson M, Heagerty A, Maccallum P, Wright D, Jespersen J
An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage.
J Thromb Haemost 2008 Jun;6(6):935-43.

Rahme E, Dasgupta K, Burman M, Yin H, Bernatsky S, Berry G, Nedjar H, Kahn SR
Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery.
CMAJ 2008 Jun 3;178(12):1545-54

Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, Mouret P, Rosencher N, Andersson M, Bylock A, Jensen E, Boberg B; on behalf of the EXTEND Study Group.
Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran.
Thromb Res 2008 May 14. [Epub ahead of print]

Bushnell BD, Anz AW, Bert JM
Venous thromboembolism in lower extremity arthroscopy
Arthroscopy 2008 May;24(5):604-11. Epub 2008 Jan 7

Devine EB, Hopefl AW, Wittkowsky AK
Adherence to guidelines for the management of excessive warfarin anticoagulation
J Thromb Thrombolysis. 2008 May 9 [Epub ahead of print]

Doggen C
Thromboprophylaxis in cancer outpatients
Blood 2008 May 15;111(10):4833

Gray E, Mulloy B, Barrowcliffe TW
Heparin and low-molecular-weight heparin.
Thromb Haemost 2008 May;99(5):807-18

Hermosillo AJ, Spinler SA
Aspirin, Clopidogrel, and Warfarin: Is the Combination Appropriate and Effective or Inappropriate and Too Dangerous?
Ann Pharmacother 2008 May 13 [Epub ahead of print]

Kahn SR, Shbaklo H, Lamping DL, Holcroft CA, Shrier I, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Johri M, Ginsberg JS
Determinants of health-related quality of life during the two years following deep venous thrombosis.
J Thromb Haemost 2008 May 3 [Epub ahead of print]

Lip GY, Boos CJ
Antithrombotic treatment in atrial fibrillation.
Postgrad Med J 2008 May; 84(991):252-8

O'Donnell M, Kearon C
Perioperative management of oral anticoagulation.
Cardiol Clin 2008 May;26(2):299-309. PMID: 18407002 [PubMed - in process]

Prandoni P, Tormene D, Perlati M, Brandolin B, Spiezia L
Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.
Expert Opin Investig Drugs 2008 May;17(5):773-7

Rubboli A, Halperin JL, Juhani Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Fat Tse H, Verheugt FW, Lip GY
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
Ann Med 2008 May 2:1-9 [Epub ahead of print]

Akl E, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schünemann H.
Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.
Cochrane Database Syst Rev 2008 Apr 16;(2):CD006650.

Akl EA, Kamath G, Yosuico V, Kim SY, Barba M, Sperati F, Cook DJ, Schünemann HJ.
Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis.
Cancer 2008 Apr 10; [Epub ahead of print]

Baglin T
Venous thromboembolism in hospitalised patients: a public health crisis?
Br J Haematol 2008 Apr 10; [Epub ahead of print]

Edwards JZ, Pulido PA, Ezzet KA, Copp SN, Walker RH, Colwell CW Jr
Portable Compression Device and Low-Molecular-Weight Heparin Compared With Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Joint Arthroplasty
J Arthroplasty 2008 Apr 1 [Epub ahead of print]

Jowett S, Bryan S, Mahé I, Brieger D, Carlsson J, Kartman B, Nevinson M
A multinational investigation of time and traveling costs in attending anticoagulation clinics.
Value Health 2008 Mar-Apr;11(2):207-12

Karnicki K, Leadley RJ Jr, Baxi S, Peterson T, Wysokinski W, McBane RD 2nd
Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
Thromb Haemost 2008 Apr;99(4):759-66

Lassen MR, Dahl O, Mismetti P, Zielske D, Turpie AG
SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study.
J Am Coll Cardiol 2008 Apr 15;51(15):1498-504

Legnani C, Palareti G, Cosmi B, Cini M, Tosetto A, Tripodi A; for the PROLONG Investigators (on behalf of FCSA Italian Federation of Thrombosis Centers)
Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG stu
Haematologica 2008 Apr 28 [Epub ahead of print]

Magee K, Campbell S, Moher D, Rowe B
Heparin versus placebo for acute coronary syndromes.
Cochrane Database Syst Rev 2008 Apr 16;(2):CD003462.

Meiltz A, Zimmermann M, Urban P, Bloch A; on behalf of the Association of Cardiologists of the Canton of Geneva.
Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world.
Europace 2008 Apr 10; [Epub ahead of print]

Prandoni P, Samama MM
Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients.
Br J Haematol 2008 Apr 13; [Epub ahead of print]

The RE-MOBILIZE Writing Committee
The Oral Thrombin Inhibitor Dabigatran Etexilate vs the North American Enoxaparin Regimen for the Prevention of Venous Thromboembolism after Knee Arthroplasty Surgery.
J Arthroplasty 2008 Apr 11 [Epub ahead of print]

Abdelhafiz AH, Wheeldon NM.
Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice.
Am J Geriatr Pharmacother 2008 Mar;6(1):1-11.

Bullock-Palmer RP, Weiss S, Hyman C
Innovative approaches to increase deep vein thrombosis prophylaxis rate resulting in a decrease in hospital-acquired deep vein thrombosis at a tertiary-care teaching hospital
J Hosp Med 2008 Mar;3(2):148-55

Paskauskas S, Pundzius J, Barauskas G
Venous thromboembolism and prophylaxis in cancer patients.
Medicina (Kaunas) 2008;44(3):175-81

Stangier J
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
Clin Pharmacokinet 2008; 47(5):285-95.

Shepherd A, Mills C
Fatal pulmonary embolism following hip and knee replacement. A study of 2153 cases using routine mechanical prophylaxis and selective chemoprophylaxis.
Hip Int. 2006 Jan-Mar; 16(1):53-6